



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**15.05.2002 Bulletin 2002/20**

(21) Application number: **00309965.2**

(22) Date of filing: **09.11.2000**

(51) Int Cl.7: **C12N 15/16**, C12N 15/62,  
C12N 15/85, C12N 5/10,  
C07K 14/60, C07K 14/61,  
A61K 38/25, A61K 38/27,  
A61K 48/00

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **Pfizer Products Inc.**  
**Groton, Connecticut 06340 (US)**


(72) Inventors:  
• **Morsey, Mohamad Al**  
**Groton, Connecticut 06340 (US)**  
• **Sheppard, Michael George**  
**Groton, Connecticut 06340 (US)**

(74) Representative: **Eddowes, Simon et al**  
**Urquhart-Dykes & Lord,**  
**30 Welbeck Street**  
**London W1G 8ER (GB)**

(54) **Growth hormone and growth hormone releasing hormone compositions**

(57) The present invention relates to methods and compositions of growth hormone and/or growth hormone releasing hormone that promote of the release and the elevation of growth hormone when administered to animals. The present invention further relates to

methods and compositions of growth hormone and/or growth hormone releasing hormone for treatment of diseases or disorders resulting from growth hormone related deficiencies. The invention also provides methods for producing novel growth hormone releasing hormone variants and their uses thereof.



**FIGURE 5**

**Description**

**[0001]** The present invention relates to novel variants of growth hormone releasing hormone (GHRH) that have enhanced resistance to enzymatic degradation and polynucleotides encoding said GHRH variants. The present invention relates to methods and therapeutic compositions for the treatment of growth hormone related deficiencies comprising administering to humans, companion animals, livestock or poultry, plasmid compositions comprising polynucleotides encoding GHRH or variants thereof, alone or in combination with polynucleotides encoding growth hormone or modified growth hormone. The present invention further relates to methods and compositions that promote the release and expression of growth hormone in order to enhance the growth and performance of companion animals, livestock or poultry comprising the administration plasmid compositions encoding GHRH variants, GHRH or modified GHRH, and/or GH or modified GH.

**Background of the Invention**

**[0002]** Growth hormone-releasing hormone ("GHRH") is a peptide hormone secreted from the hypothalamus. Following secretion, GHRH enters the portal circulation connecting the hypothalamus to pituitary gland. GHRH then interacts with its receptors on the pituitary gland and induces the release of growth hormone ("GH"). GH secreted from the pituitary gland enters the general circulation and from there it reaches various organs and tissues of the body where it interacts with specific receptors and induces a wide range of developmental effects.

**[0003]** GHRH peptides have been isolated and characterized from several species including humans, porcine, ovine and bovine. In each of these species, GHRH is a small polypeptide consisting of 44 amino acids (GHRH(1-44)-NH<sub>2</sub>). However, it has been also shown that smaller fragments, most notably those consisting of the first (amino terminal) 29 amino acids (referred to as GHRH1-29 fragment) retain the same intrinsic biological activity as the full length parent molecule.

**[0004]** GHRH is synthesized as a precursor polypeptide consisting of 107 or 108 amino acids depending on the species. Following synthesis, the precursor GHRH polypeptide undergoes sequential processing. First, the 31 amino acid signal peptide (Met<sup>30</sup> to Arg<sup>0</sup>) of the GHRH precursor polypeptide is cleaved (Smith et al., 1992, *Biotechnology* 10:315-319). Subsequently, the GHRH precursor polypeptide is cleaved at position 46-47 and at position 45-46 by a trypsin-like endopeptidase and a carboxypeptidase, respectively, resulting in generation of GHRH(1-45)-OH and a 30 amino acid peptide (amino acids 77-107) designated GCTP (Brar, A.K. et al., 1991, *Endocrinology* 129: 3274-3280). The GHRH(1-45)-OH polypeptide is further processed by peptidyl glycine  $\alpha$ -amidating monooxygenase ("PAM"), which transfers an amide group from Gly<sup>45</sup> to Leu<sup>44</sup> and results in the formation of GHRH(1-44)-NH<sub>2</sub>, the full length form of GHRH (Brar, A.K. et al., 1991, *Endocrinology* 129: 3274-3280). The GCTP is also undergoes processing by PAM, which results in the transfer of an amide group from Gly<sup>77</sup> to Gln<sup>76</sup>. Although the role of GHRH(1-44)-NH<sub>2</sub> in inducing the release of GH is well established, the role of the GCTP peptide is less clear. One report has implicated the GCTP peptide in the control of feeding behavior (Arase, K. et al., 1987, *Endocrinology* 121:1960-1965).

**[0005]** GH has been identified and its gene cloned from many species including human, porcine, bovine, and equine. Unlike GHRH, there exists natural variants of GH within a given species. For example, bovine GH is released from the pituitary gland in one of four variants which differ from one another by one or more amino acids and some studies suggest that these variants differ in their potency (*e.g.*, in terms of their ability to increase milk yield). Several studies have also identified amino acid substitutions that lead to an increase in the affinity of GH to its receptors and/or enhanced stability to enzymatic degradation. Studies have also shown that immunization against specific peptides from GH (*e.g.*, a peptide consisting of amino acids 35 to 53 of GH) leads to production of antibodies that bind growth hormone and increase the efficacy of GH treatment, presumably because the antibodies delay the clearance of GH from circulation, thus, increasing half-life of GH, and/or protect GH from proteolytic degradation (Bomford, F. and Aston, P., 1990, *Endocrinology* 125:31-38).

**[0006]** Significant research efforts have focused on the structural attributes of GH and GHRH, as well as their biological and developmental activities. A number of groups have attempted to exploit GH and GHRH in a manner that could provide important therapeutic and economic benefits as a result of their use in humans and animals. For example, the traditional treatment of GH-deficient children has been the administration of growth hormone isolated from human pituitary glands, however these preparations are no longer available in the United States due to virus-contaminated samples (Vance, 1990, *Clin. Chem* 36/3: 415-420). Recombinantly expressed and purified GH have been shown to have some benefits in treating GH-deficient children, however the combination of recombinantly expressed GH and GHRH in the treatment of GH-deficient children has provided conflicting results. (Vance, *supra*). Further, purified GH and GHRH must be administered at very high quantities to be effective as the exposure of these polypeptides to serum results in their rapid degradation to a polypeptide which exhibits considerably different biological and pharmacokinetic properties. (Fronman et al., 1989, *J. Clin. Invest.* 83:1533-1540).

**[0007]** Other studies have shown that GH or GHRH administered as purified polypeptides have significant impact

on animal growth (muscle and bone growth), average daily gain, milk production, feed efficiency (the ratio of feed consumed to body weight gain), adipose tissue accretion and others. For example, it has been shown that daily administration of maximally effective doses of GH administered to growing pigs for 33-77 days can increase average daily gain -10-20%, improves feed efficiency 13-33%, decrease adipose tissue accretion by as much as 70%, and stimulates protein deposition (muscle growth) by as much as 62%. (Etherton et al., 1998, *Physiological Reviews* 78: 745-761). Furthermore, when GH was administered to dairy cows, milk yields were increased by 10-15% (□4-6kg/day) (Etherton et al., 1998, *Physiological Reviews* 78:745-761).

**[0008]** A major impediment to fulfilling the therapeutic and economic potential of GHRH peptides is their susceptibility to cleavage (and subsequent conversion to inactive forms) by specific tissue and plasma proteolytic enzymes; most notably dipeptidylpeptidase IV ("DPPIV"). A number of researchers have focused on manipulating GHRH in order to develop compounds with significant therapeutic potential. Consequently, a wide variety of synthetic GHRH peptide analogues have been produced. They consist of GHRH polypeptides in which one or more amino acids have been chemically modified or replaced with other L- or D- amino acids. These modifications or substitutions are designed to yield analogues with biological properties superior to those of the parent molecule in terms of potency, stability and resistance to chemical and enzymatic degradation. However, these chemically modified polypeptides are not easily or efficiently produced in a suitable form to be administered to humans or animals.

**[0009]** In spite of the significant therapeutic and economic benefits of GH or GHRH alluded to above, exogenous supplementation of animals with GH or GHRH proteins have not been widely adopted as a component of routine management practices to enhance the quality of meat from animals and/or enhance the productivity of livestock. This is because in order to get these benefits, animals have to be repeatedly administered GH or GHRH polypeptides (often daily, but typically in a slow release formulation given every 7-10 days). (Etherton, T.D., 1997, *Nature Biotechnology* 15:1248) This situation is labor intensive, time consuming, expensive, and does not fit current management practices where animals are reared in large numbers and are handled very infrequently, it is apparent therefore that in order to realize the therapeutic and economic benefits of GH and/or GHRH administration, much improved formulations for delivery of these hormones must be developed to overcome the current limitations of their use; namely the need for repeated administration.

#### Summary of the Invention

**[0010]** The present invention relates to novel variants of GHRH that have enhanced resistance to enzymatic degradation and polynucleotides encoding said variants. The present invention also relates to pharmaceutical formulations comprising polynucleotide sequences encoding GHRH variants alone or in combination with polynucleotide sequences encoding GHRH, modified GHRH, GH and/or modified GH. The present invention also relates to pharmaceutical formulations comprising GHRH variant peptides alone or in combination with GHRH polypeptides, modified GHRH polypeptides, GH polypeptides and/or modified GH polypeptides. The present invention further relates to pharmaceutical formulations comprising canine or feline GHRH peptides alone or in combination with GHRH variant polypeptides, modified GHRH polypeptides, GH polypeptides and/or modified GH polypeptides.

**[0011]** The present invention relates to therapeutic methods and compositions for the treatment of growth hormone related deficiencies comprising growth hormone ("GH") and/or growth hormone-releasing hormone ("GHRH") in human, companion animals, livestock and poultry. The invention also relates to methods for the improvement in the health of humans, companion animals, livestock and poultry. The invention also relates to methods for the treatment of obesity and frailty of companion animals. The invention further relates to methods for the enhancement of the growth and performance of companion livestock and poultry. The methods of the present invention comprise pharmaceutical compositions which enhance the expression of growth hormone or promote the release of growth hormone or both when administered to humans, companion animals, livestock or poultry. According to the present invention, the term "GHRH" relates to the full length wildtype form of GHRH which is 44 amino acids (aa) or a precursor form of GHRH. In accordance with the present invention, the term "modified GHRH" refers to any amino terminal polypeptide fragment of GHRH from 29 amino acids to 107 or 108 amino acids in length and any mutant of GHRH, including additions, deletions or substitutions at the nucleotide or amino acid level, which retains at least the level of activity of wildtype GHRH, that is, the ability to induce GH gene transcription at levels comparable to wildtype GHRH.

**[0012]** In accordance with the present invention, the term "GHRH variant" relates to a GHRH polypeptide to which one or more amino acids have been attached to the carboxy or amino terminus of the polypeptide, or a wildtype GHRH polypeptide that contains a substitution of one or more amino acids, so that the GHRH variant retains at least equal or enhanced wildtype GHRH activity and has enhanced resistance to enzymatic degradation relative to the wildtype GHRH. In accordance with the present invention, wildtype GHRH activity is measured by its ability to induce GH gene transcription. In accordance with the present invention, resistance to enzymatic degradation is determined by the ability of the polypeptide to resist degradation caused by dipeptidylpeptidase type IV.

**[0013]** According to the present invention, the term "GH" refers to the full length wildtype form of GH, which is 191

amino acids, and "modified GH" refers to any fragment of GH and any mutant including additions, deletions or substitutions at the nucleotide or amino acid level, which retains at least the level of wildtype activity of GH, that is, the ability to induce insulin growth factor (IGF) gene transcription at levels comparable to wildtype GH, or mimic the anti-adipogenic and lipolytic effects of GH.

#### Description of the Figures

##### [0014]

Figure 1 is a map of the pGHRH-4 construct (SEQ ID No. 47).  
 Figure 2 is a map of the pGHRH1-44SK construct (SEQ ID No. 48).  
 Figure 3 is a map of the pGHRH1-44WTSK685 construct (SEQ ID No. 49).  
 Figure 4 is a map of the pGHRH1-44WTSK2014 construct (SEQ ID No. 50).  
 Figure 5 is a graph depicting the GHRH expression levels detected in supernatants from pGHRH-4 transfected cells.

#### Detailed description of the invention

**[0015]** The present invention relates to novel variants of GHRH that have enhanced resistance to enzymatic degradation and polynucleotides encoding said GHRH variants. The present invention relates to pharmaceutical compositions which promote the release and/or expression of GH. In particular, the pharmaceutical compositions of the present invention comprise polynucleotide sequences encoding GHRH variants alone or in combination with polynucleotide sequences encoding GHRH, modified GHRH, GH and/or modified GH or any combination thereof. In another embodiment, the pharmaceutical compositions of the present invention comprise GHRH variant polypeptides alone or in combination with GHRH polypeptides, GHRH modified polypeptides, GH polypeptides or GH modified polypeptides or any combination thereof.

**[0016]** The present invention relates to methods of treating disorders related to GH related deficiencies in humans, companion animals, livestock and poultry, comprising administering pharmaceutical formulations which enhance GH expression and/or release. The present invention further relates to methods of treating livestock and poultry in order to enhance growth and performance comprising administering pharmaceutical formulations which enhance GH expression and/or release.

**[0017]** The pharmaceutical formulations to be administered in accordance with the methods of the present invention encompass plasmid compositions comprising (a) polynucleotide sequences encoding GHRH variants; (b) polynucleotide sequences encoding GHRH or modified GHRH; (c) polynucleotide sequences encoding GH or modified GH; or any combination thereof, wherein the polynucleotide sequences are operably linked to a promoter or regulatory element, preferably one that is transcriptionally active in muscle tissue. The pharmaceutical formulations to be administered in accordance with the methods of the present invention also include: i) plasmid compositions comprising polynucleotides encoding for GH or modified or variant GHRH gene; ii) plasmid compositions comprising polynucleotides encoding for both GH and GHRH genes; iii) plasmid compositions comprising polynucleotides encoding for a GHRH gene, a GH gene or a gene encoding a fusion protein consisting of a peptide from GH and a carrier protein for induction of GH potency-enhancing antibodies; (iv) recombinant proteins, peptides, fragments or derivatives thereof comprising canine GHRH or feline GHRH; (v) recombinant proteins, peptides, fragments or derivatives thereof of the GHRH variants of the present invention; and (vi) recombinant fusion proteins, peptides, fragments or derivatives thereof comprising GH and GHRH.

**[0018]** In one embodiment, the pharmaceutical compositions of the present invention comprise polynucleotide sequences encoding canine or feline GHRH alone or in combination with polynucleotide sequences encoding GHRH variant, modified GHRH, GH and/or modified GH or any combination thereof. In another embodiment, the pharmaceutical compositions of the present invention comprise canine or feline GHRH polypeptides alone or in combination with GHRH variant polypeptides, modified GHRH, GH polypeptides or GH modified polypeptides or any combination thereof. The pharmaceutical compositions of the present invention are in suitable formulation to be administered to humans, companion animals, livestock or poultry for the treatment of growth hormone related deficiencies or the enhancement of growth and performance of livestock and poultry. The pharmaceutical compositions of the present invention are also in suitable formulation for the treatment of obesity and frailty of companion animals or the improvement in the health of humans, companion animals, livestock, and poultry.

**[0019]** The present invention relates to therapeutic methods and compositions for the treatment of growth hormone related deficiencies comprising growth hormone ("GH"); modified GH; growth hormone releasing hormone ("GHRH"); GHRH variants; modified GHRH or any combination thereof. The therapeutic compositions of the invention are administered to animals, preferably to mammals, more preferably to companion animals (*e.g.*, dogs, cats and horses), live-

stock (*e.g.*, cows and pigs) and poultry (*e.g.*, chickens and turkeys), and most preferably to humans. The invention also relates to methods and compositions for the enhancement of the growth and performance of animals, more preferably mammals, and most preferably livestock (*e.g.*, cows and pigs) and poultry (*e.g.*, chickens and turkeys) with the proviso that such compositions are not to be administered to mice, rats, rodents, guinea pigs, or rabbits. The invention

5 also relates to methods and compositions for the treatment of obesity and frailty of animals, preferably to mammals, more preferably to companion animals (*e.g.*, dogs, cats and horses). The invention further relates to methods and compositions for the improvement in the health of animals, preferably to mammals, more preferably to companion animals (*e.g.*, dogs, cats and horses), livestock (*e.g.*, cows and pigs) and poultry (*e.g.*, chickens and turkeys), and most preferably to humans.

10 **[0020]** The present invention is based in part of the discovery of recombinantly engineered GHRH variants which retain at least the level of activity wildtype GHRH, that is the ability to induce GH gene transcription at levels comparable to wildtype GHRH, and which have enhanced resistance to enzymatic degradation relative to the wildtype GHRH. The GHRH variants of the present invention may be recombinantly expressed at high levels in host cells and easily isolated and purified in a form suitable for administration to humans and animals. Thus, the GHRH variants of the present

15 invention may be efficiently produced and isolated at high levels as opposed to modified GHRH polypeptides in the art which are modified using traditional chemistry methods to introduce modifications in the native GHRH sequence.

**[0021]** In one embodiment, a GHRH variant of the present invention comprises the addition of one amino acid, preferably a hydrophobic residue and more preferably a tyrosine residue, to the amino terminus (position 1) of GHRH. In another embodiment, a GHRH variant comprises the addition of two amino acids, wherein the second amino acid is not proline or alanine, to the amino terminus (position 1) of GHRH. In another embodiment, a GHRH variant comprises the addition of three amino acids, wherein the second amino acid is proline or alanine, to the amino terminus (position 1) of GHRH. In another embodiment, a GHRH variant comprises the addition of more than three amino acids to the amino terminus (position 1) of GHRH, wherein the addition does not interfere with the functional activity of GHRH, that is, the ability of GHRH to induce GH gene transcription. In a preferred embodiment of the present invention, a GHRH

20 variant comprises the addition of a tripeptide to the amino terminus, wherein the tripeptide is diproton A or diproton B or a peptide with a structure analogous to diproton A or diproton B. In yet another embodiment, a GHRH variant comprises the addition of glycine and arginine at the carboxy-terminus. This addition results in the amidation of GHRH; the glycine and arginine is cleaved off and the last amino acid before the added glycine is amidated.

**[0022]** In one embodiment, a GHRH variant comprises any of the amino acid additions described above and the substitution of glycine with alanine at residue 15. In another embodiment, a GHRH variant comprises any of the amino acid additions described above and the substitution of leucine with alanine at residue 22. In another embodiment, a GHRH variant comprises any of the amino acid additions described above and the substitutions of glycine with alanine at residue 15 and leucine with alanine at residue 22. In another embodiment, a GHRH variant comprises any of the amino acid additions at the amino terminus and the amino acid additions at the carboxy-terminus. In another embodiment, a GHRH variant comprises any of the amino acid additions at the amino terminus described above, the amino acid additions at the carboxy-terminus described above, and the substitution of glycine to alanine at residue 15. In another embodiment, a GHRH variant comprises any of the amino acid additions at the amino terminus described above, the amino acid additions at the carboxy-terminus described above, and the substitution of leucine to alanine at residue 22. In yet another embodiment, a GHRH variant comprises any of the amino acid additions at the amino terminus described above, the amino acid additions at the carboxy-terminus described above, and the substitutions of glycine to alanine at residue 15 and leucine to alanine at residue 22. The term "GHRH precursor variant" as used herein refers to a precursor form of the full length wildtype GHRH polypeptide to which one or more amino acids have been attached to the amino terminus of the polypeptide and/or contains a substitution of one or more amino acids, so that the GHRH precursor variant retains at least equal or enhanced wildtype GHRH activity and has enhanced resistance to enzymatic degradation relative to wildtype GHRH. In one embodiment of the present invention, a GHRH precursor variant comprises the amino acid additions and/or the amino acid substitutions described above. The present invention also encompasses a fusion variant comprising any of the GHRH variants described above and GH or modified GH. The term "fusion variant" as used herein refers to a fusion protein comprising GHRH variants or modified GHRH and GH or modified GH. In one embodiment of the present invention, a fusion variant comprises any of the GHRH variants described above, which consist of amino acid additions at the amino terminus and/or amino acid substitutions, and GH or modified GH.

30

35

40

45

50

**[0023]** The modifications and/or substitutions of GHRH described herein are made to GHRH polypeptides which retain the biological activity at least equal to the full length wildtype GHRH, preferably a precursor form of GHRH, more preferably the sequence of GHRH consisting of about 29 amino acids to about 44 amino acids. The polynucleotide sequences encoding the GHRH variants described herein are also within the scope of the present invention. The present invention provides that the polypeptides are encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By "degenerate variant" is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (*e.g.*, an ORF) by nucleotide

55

sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins. The present invention encompasses GHRH variants encoded by the polynucleotide sequence any species.

**[0024]** The present invention encompasses polynucleotide sequences encoding precursor forms of GHRH, full length wildtype GHRH, modified GHRH, GHRH variants, and fragments of GHRH from 29 amino acids to 44 amino acids in length for any species, which retain at least the activity of wildtype GHRH. For example, the polynucleotide sequences encoding human, swine, and bovine growth hormone releasing hormone disclosed in Genbank accession number SEG\_HSGHRH, accession number U90275, and accession number U29611, respectively, are incorporated herein by reference. The present invention also encompasses polynucleotide sequences encoding GHRH polypeptides disclosed for any species (*e.g.*, the polynucleotide sequence encoding the human GHRH precursor polypeptide disclosed in Genbank accession number P01286 is incorporated herein by reference). The present invention further encompasses polynucleotide sequences encoding full length wildtype GH or modified GH for any species. For example, the polynucleotide sequences encoding human, swine, and bovine growth hormone disclosed in Genbank accession number J03071, accession number U19787, and accession number E00293, respectively, are incorporated herein by reference. The present invention also encompasses polynucleotide sequences encoding GH polypeptides disclosed for any species (*e.g.*, the polynucleotide sequence encoding the bovine GH polypeptide disclosed in Genbank accession number STBO is incorporated herein by reference).

**[0025]** The polynucleotide sequence encoding GHRH, modified GHRH or GHRH variants can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The polynucleotide sequence encoding GH or modified GH can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native GH or native GHRH genes or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In one embodiment, the wildtype or modified human GH gene is expressed. In another embodiment, the wildtype, modified or variant human GHRH is expressed. In yet another embodiment, the wildtype or modified human GH and the wildtype, modified or variant human GHRH gene are expressed.

**[0026]** Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene, comprising GH or modified GH and GHRH, modified GHRH or GHRH variants, consisting of appropriate transcriptional and translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of the nucleic acid sequence encoding GH or modified GH may be regulated by a second nucleic acid sequence so that the GH or modified GH is expressed in a host transformed with the recombinant DNA molecule. Expression of the nucleic acid sequence encoding GHRH, modified GHRH or GHRH variant may be regulated by a second nucleic acid sequence so that the GHRH modified GHRH or GHRH variant is expressed in a host transformed with the recombinant DNA molecule. For example, expression of GH or GHRH may be controlled by any promoter or enhancer element known in the art. Promoters which may be used to control GH and/or GHRH gene expression include, but are not limited to, the Cytomegalovirus (CMV) immediate early promoter region, the SV40 early promoter region (Bernoist and Chambon, 1981, *Nature* 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, *Proc. Natl. Acad. Sci. USA* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, *Nature* 296:39-42); prokaryotic expression vectors such as the  $\beta$ -lactamase promoter (Villa-Kamaroff et al., 1978, *Proc. Natl. Acad. Sci. USA* 75:3727-3731), or the *tac* promoter (DeBoer et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:21-25); see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; plant expression vectors comprising the nopaline synthetase promoter region (Herrera-Estrella et al., *Nature* 303:209-213) or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., 1981, *Nucl. Acids Res.* 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, *Nature* 310:115-120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, *Cell* 38:639-646; Ornitz et al., 1986, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409; MacDonald, 1987, *Hepatology* 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, *Nature* 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, *Cell* 38:647-658; Adames et al., 1985, *Nature* 318:

533-538; Alexander et al., 1987, *Mol. Cell. Biol.* 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, *Cell* 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, *Genes and Devel.* 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, *Mol. Cell. Biol.* 5:1639-1648; Hammer et al., 1987, *Science* 235:53-58; alpha-1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, *Genes and Devel.* 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogam et al., 1985, *Nature* 315:338-340; Kollias et al., 1986, *Cell* 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, *Cell* 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, *Nature* 314:283-286), swine alpha-skeletal actin control region which is active in muscle (Reecy, M. et al., 1998, *Animal Biotechnology* 9:101-120) and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, *Science* 234:1372-1378).

**[0027]** In a specific embodiment, a vector is used that comprises a promoter operably linked to GH- or modified GH-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (*e.g.*, an antibiotic resistance gene). In another embodiment, a vector is used that comprises a promoter operably linked to GHRH-, modified GHRH- or GHRH variant-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (*e.g.*, an antibiotic resistance gene). In yet another embodiment, a vector is used that comprises a promoter operably linked to GH or modified GH and GHRH, modified GHRH or GHRH variant-encoding nucleic acids, one or more origins of replication, and, optionally, one or more selectable markers (*e.g.*, an antibiotic resistance gene).

**[0028]** Expression vectors containing gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of the GH- or modified GH-encoding polynucleotides and GHRH-, modified GHRH- or GHRH variant-encoding polynucleotides inserted in an expression vector(s) can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to the inserted genes. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (*e.g.*, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of the gene(s) in the vector(s). For example, if the GH gene is inserted within the marker gene sequence of the vector, recombinants containing the GH gene insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the gene product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the GH and GHRH in *in vitro* assay systems, *e.g.*, binding of GH with anti-GH antibody or binding of GHRH with anti-GHRH antibody.

**[0029]** Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (*e.g.*, lambda), and plasmid and cosmid DNA vectors, to name but a few.

**[0030]** In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (*e.g.*, glycosylation, phosphorylation of proteins). Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

**[0031]** For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the differentially expressed or pathway gene protein may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (*e.g.*, promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the differentially expressed or pathway gene protein. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous

activity of the differentially expressed or pathway gene protein.

**[0032]** A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, *Cell* 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, *Proc. Natl. Acad. Sci. USA* 48:2026), and adenine phosphoribosyltransferase (Lowy et al., 1980, *Cell* 22:817) genes can be employed in tk<sup>-</sup>, hgp<sup>+</sup> or apt<sup>-</sup> cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler et al., 1980, *Natl. Acad. Sci. USA* 77:3567; O'Hare et al., 1981, *Proc. Natl. Acad. Sci. USA* 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., 1981, *J. Mol. Biol.* 150:1); and hyg<sup>+</sup>, which confers resistance to hygromycin (Santerre et al., 1984, *Gene* 30:147) genes.

**[0033]** The present invention provides for the treatment or prevention of GH associated diseases or disorders, including those disorders characterized by GH deficiency, comprising the administration of a pharmaceutical formulation to a human, companion animal, livestock or poultry which enhances GH expression and/or release. The present invention also provides for methods and protocols to enhance the growth and performance of livestock and poultry, comprising the administration of a pharmaceutical formulation to a companion animal, livestock or poultry which enhances GH expression and/or release. The present invention also provides for the treatment of obesity and frailty, comprising the administration of a pharmaceutical formulation to a companion animal which enhances or modulates GH expression and/or release. The present invention further provides for methods for the improvement in health, comprising the administration of a pharmaceutical formulation to a human, companion animal, livestock or poultry which enhances GH expression and/or release. In accordance with the invention, methods of the present invention encompass the administration of pharmaceutical formulations comprising: (a) polynucleotide sequences encoding GHRH variants alone or in combination with polynucleotide sequences encoding GHRH, modified GHRH, GH, modified GH or any combination thereof, wherein the polynucleotide sequences are operably linked to a promoter or regulatory element, preferably one that is transcriptionally active in muscle tissue; (b) polynucleotide sequences encoding canine or feline GHRH alone or in combination with polynucleotide sequences encoding GHRH variants, modified GHRH, GH, modified GH or any combination thereof, wherein the polynucleotide sequences are operably linked to a promoter or regulatory element, preferably one that is transcriptionally active in muscle tissue; (c) polynucleotide sequences encoding GHRH, modified GHRH, GH, modified GH or any combination thereof wherein the polynucleotide sequences are operably linked to a promoter or regulatory element, preferably one that is transcriptionally active in muscle tissue; (c) variant GHRH polypeptides alone, expressed as a fusion protein, or in combination with GHRH, modified GHRH, GH or modified GH polypeptides or any combination thereof; or (d) canine or feline GHRH polypeptides alone, expressed as a fusion protein, or in combination with GHRH variants, modified GHRH, GH or modified GH polypeptides or any combination thereof.

**[0034]** Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human GH and/or GHRH genes, gene fragments or derivatives thereof are administered to a human patient for therapy or prophylaxis.

**[0035]** In a specific embodiment, nucleic acids comprising sequences encoding GH and/or GHRH or functional derivatives thereof, are administered to promote the release and/or elevation of growth hormone, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediate a therapeutic effect by promoting the function of GH.

**[0036]** Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

**[0037]** For general reviews of the methods of gene therapy, see Goldspiel et al., 1993, *Clinical Pharmacy* 12:488-505; Wu and Wu, 1991, *Biotherapy* 3:87-95; Tolstoshev, 1993, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596; Mulligan, 1993, *Science* 260:926-932; and Morgan and Anderson, 1993, *Ann. Rev. Biochem.* 62:191-217; May, 1993, *TIBTECH* 11(5): 155-215). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY; and Kriegler, 1990, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY.

**[0038]** In a preferred aspect, the compound comprises nucleic acid sequences encoding GH or modified GH and GHRH, modified GHRH or GHRH variants, said nucleic acid sequences being part of expression vectors that express GH or modified GH and GHRH, modified GHRH or GHRH variants in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the GH or modified GH and GHRH, modified GHRH or GHRH variants coding regions, said promoters being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the GH or modified GH and GHRH, modified GHRH or GHRH variants coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the GH or modified GH and GHRH, modified GHRH or GHRH variants nucleic acids (Koller and Smithies, 1989, *Proc. Natl. Acad. Sci. USA*



86:8932-8935; Zijlstra et al., 1989, *Nature* 342:435-438).

[0039] Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids *in vitro*, then transplanted into the patient. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

[0040] In a specific embodiment, the nucleic acid sequences are directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, *e.g.*, by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, *e.g.*, by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, *e.g.*, Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (see, *e.g.*, PCT Publications WO 92/06180 dated April 16, 1992 (Wu et al.); WO 92/22635 dated December 23, 1992 (Wilson et al.); WO92/20316 dated November 26, 1992 (Findeis et al.); WO93/14188 dated July 22, 1993 (Clarke et al.), WO 93/20221 dated October 14, 1993 (Young)). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, *Proc. Natl. Acad. Sci. USA* 86:8932-8935; Zijlstra et al., 1989, *Nature* 342:435-438).

[0041] In a specific embodiment, viral vectors that contain nucleic acid sequences encoding GH or modified GH and/or GHRH, modified GHRH or GHRH variants are used. For example, a retroviral vector can be used (see Miller et al., 1993, *Meth. Enzymol.* 217:581-599). These retroviral vectors have been to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA. The nucleic acid sequences encoding the GH or modified GH and GHRH, modified GHRH or GHRH variants to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., 1994, *Biotherapy* 6:291-302, which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., 1994, *J. Clin. Invest.* 93:644-651; Kiem et al., 1994, *Blood* 83:1467-1473; Salmons and Gunzberg, 1993, *Human Gene Therapy* 4:129-141; and Grossman and Wilson, 1993, *Curr. Opin. in Genetics and Devel.* 3:110-114.

[0042] Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, 1993, *Current Opinion in Genetics and Development* 3:499-503 present a review of adenovirus-based gene therapy. Bout et al., 1994, *Human Gene Therapy* 5:3-10 demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., 1991, *Science* 252:431-434; Rosenfeld et al., 1992, *Cell* 68:143-155; Mastrangeli et al., 1993, *J. Clin. Invest.* 91:225-234; PCT Publication WO94/12649; and Wang, et al., 1995, *Gene Therapy* 2:775-783. In a preferred embodiment, adenovirus vectors are used. Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., 1993, *Proc. Soc. Exp. Biol. Med.* 204:289-300; U.S. Patent No. 5,436,146).

[0043] Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

[0044] In this embodiment, the nucleic acid is introduced into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, *e.g.*, Loeffler and Behr, 1993, *Meth. Enzymol.* 217:599-618; Cohen et al., 1993, *Meth. Enzymol.* 217:618-644; Cline, 1985, *Pharmac. Ther.* 29:69-92) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

**[0045]** The resulting recombinant cells can be delivered to a subject by various methods known in the art. Recombinant blood cells (*e.g.*, hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, subject's state, etc., and can be determined by one skilled in the art.

**[0046]** Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, *e.g.*, as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

**[0047]** In a preferred embodiment, the cell used for gene therapy is autologous to the subject.

**[0048]** In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding GH or modified GH and/or GHRH, modified GHRH or GHRH variants are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained *in vitro* can potentially be used in accordance with this embodiment of the present invention (see *e.g.* PCT Publication WO 94/08598, dated April 28, 1994; Stemple and Anderson, 1992, *Cell* **71**:973-985; Rheinwald, 1980, *Meth. Cell Bio.* **21A**:229; and Pittelkow and Scott, 1986, *Mayo Clinic Proc.* **61**:771).

**[0049]** In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

**[0050]** The polypeptides of the invention include polypeptides which comprise the amino acid sequence of canine or feline GHRH. The polypeptides of the invention also include polypeptides which comprise the amino acid sequence of a GHRH variant of the present invention. The polypeptides of the invention further include polypeptides which comprise the amino acid sequence of GH or modified and GHRH or modified GHRH. Protein compositions of the present invention may further comprise an acceptable carrier, such as a hydrophilic, *e.g.*, pharmaceutically acceptable, carrier.

**[0051]** The invention also relates to methods for producing a polypeptide comprising growing a culture of the cells of the invention in a suitable culture medium, and purifying the protein from the culture. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, and further purified.

**[0052]** The present invention further provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By "degenerate variant" is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (*e.g.*, an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins. A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. This is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. In an alternative method, the polypeptide or protein is purified from bacterial cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-affinity chromatography. See, *e.g.*, Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag (1994); Sambrook, *et al.*, in *Molecular Cloning: A Laboratory Manual*; Ausubel *et al.*, *Current Protocols in Molecular Biology*.

**[0053]** The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell, through genetic manipulation, is made to produce a polypeptide or protein which it normally does not produce or which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention. The purified polypeptides can be used in *in vitro* binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but are not limited to, for *e.g.*, small molecules, molecules from combinatorial libraries, antibodies or other proteins.

**[0054]** The protein of the invention may also be expressed as a product of transgenic animals, *e.g.*, as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

**[0055]** The protein may also be produced by known conventional chemical synthesis. Methods for constructing the

proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

**[0056]** The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBat.RTM. kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

**[0057]** The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl.RTM. or Cibacrom blue 3GA Sepharose.RTM.; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

**[0058]** Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and In Vitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, Conn.).

**[0059]** Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

**[0060]** The compounds of the invention are preferably tested *in vitro*, and then *in vivo* for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays which can be used to determine whether administration of a specific compound is indicated, include *in vitro* cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

**[0061]** The expression of GH or modified GH and GHRH, modified GHRH or GHRH variants can be assayed by the immunoassays, gel electrophoresis followed by visualization, or any other method known to those skilled in the art.

**[0062]** In various specific embodiments, *in vitro* assays can be carried out with representative cells of cell types involved in a patient's disorder, to determine if a compound has a desired effect upon such cell types. In accordance with the present invention, the functional activity of GHRH can be measured by its ability to induce GH gene transcription *in vitro*. In accordance with the present invention, the functional activity of GHRH can be measured by its ability to induce IGF gene transcription *in vitro*.

**[0063]** Compounds for use in therapy can be tested in suitable animal model systems prior to testing in humans, including but not limited to pigs, chicken, cows or monkeys.

**[0064]** The invention provides methods of treatment (and prophylaxis) by administration to a subject of an effective amount of a compound of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human. In a specific embodiment, a non-human mammal is the subject.

**[0065]** Formulations and methods of administration that can be employed when the compound comprises a nucleic acid are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

**[0066]** Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intratumoral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered

together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be

employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

**[0067]** In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, nonporous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.

**[0068]** In another embodiment, the compound can be delivered in a vesicle, in particular a liposome (*see* Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see generally ibid.*)

**[0069]** In yet another embodiment, the compound can be delivered in a controlled release system. In one embodiment, a pump may be used (*see* Langer, *supra*; Sefton, *CRC Crit. Rev. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (*see* Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); *see also* Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, *i.e.*, the brain, thus requiring only a fraction of the systemic dose (*see, e.g.*, Goodson, in *Medical Applications of Controlled Release, supra*, vol. 2, pp. 115-138 (1984)).

**[0070]** Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

**[0071]** In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by use of a retroviral vector (*see* U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (*see e.g.*, Joliet et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:1864-1868), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

**[0072]** The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

**[0073]** In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized

powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

**[0074]** The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

**[0075]** The amount of the compound of the invention which will be effective in the treatment of cancer can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

**[0076]** Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

**[0077]** The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

## EXAMPLES

### CLONING OF CANINE AND FELINE GHRH

#### 1. CLONING OF CANINE GHRH

**[0078]** In order to clone the canine GHRH, the canine genomic library (Clonetech Lab) is screened with the radioactively labeled fragment encoding the porcine GHRH (SEQ ID No. 1) following protocols known to one of ordinary skill in the art. The fragment encoding the porcine GHRH (SEQ ID No. 1) is labeled using commercially available DNA labeling kits as recommended by the manufacturer. Clones identified that contain the gene coding for the canine precursor GHRH are isolated and sequenced by methods known to one of ordinary skill in the art. The sequence results obtained from sequencing both DNA strands of a clone is compared with sequences of known GHRH species and the canine GHRH is subcloned into appropriate plasmid vectors (e.g., pVR1012; Vical, San Diego, CA) according to protocols known to one of ordinary skill in the art.

#### 2. CLONING OF FELINE GHRH

**[0079]** In order to clone the feline GHRH, the feline genomic library (Clonetech Lab) is screened with the radioactively labeled fragment encoding the porcine GHRH (SEQ ID No. 1) following protocols known to one of ordinary skill in the art. The fragment encoding the porcine GHRH (SEQ ID No. 1) is labeled using commercially available DNA labeling kits as recommended by the manufacturer. Clones identified that contain the gene coding for the feline precursor GHRH are isolated and sequenced by methods known to one of ordinary skill in the art. The sequence results obtained from sequencing both DNA strands of a clone is compared with sequences of known GHRH species and the feline GHRH is subcloned into appropriate plasmid vectors (e.g., pVR1012; Vical, San Diego, CA) according to protocols known to one of ordinary skill in the art.

### SYNTHESIS OF GHRH CONSTRUCTS

#### 3. pGHRH-4 (pGHRH1-44WTCMV)

**[0080]** In order to construct a plasmid containing the gene that codes for the natural porcine GHRH polypeptide and to have the latter secreted into the blood circulation when such plasmids are injected into animals, primers designated GHRH-1 (SEQ ID No. 61), GHRH-2 (SEQ ID No. 62), GHRH-4 (SEQ ID No. 66), and GHRH-7 (SEQ ID No. 67) were

synthesized. The primers were used in reverse transcription polymerase chain reactions (RT-PCRs) to amplify the human GHRH signal sequence from human mRNA and the porcine GHRH protein sequence from porcine mRNA. The resulting PCR-amplified human GHRH signal sequence and porcine GHRH protein sequence were digested with Bgl II and Bam HI, respectively. Then the fragments were ligated together and cloned into the Bam HI site of the plasmid pVR1012 (Vical, San Diego, CA) to produce a plasmid designated pGHRH-4 (Figure 1). The expression of the GHRH oligonucleotide (SEQ ID Nos. 1 and 2), which encodes a 75 amino acid polypeptide comprising the porcine GHRH protein sequence (44 amino acids) preceded by the signal sequence from human GHRH protein (31 amino acids), is driven by Cytomegalo-virus immediate early (CMV IE) promoter/enhancer element.

4. pGHRH1-44WTSK685:

**[0081]** A plasmid containing the polynucleotide sequences encoding the 75-amino acid GHRH protein described above driven by a 685 bp fragment derived from the swine  $\alpha$ -skeletal actin promoter (SEQ ID No. 3) was constructed as described below.

**[0082]** The oligonucleotide fragment encoding the 75 amino acid GHRH protein (SEQ ID No. 1) was PCR-amplified from plasmid pGHRH-4 using a primer designated p97-S1 containing a Hind III site (SEQ ID No. 4) and a primer designated p97-A258, containing an Xba I site (SEQ ID No. 5). The PCR-amplified sequence was then cloned into the Hind III-Xba I site of plasmid pGL3 basic (Promega) to produce a plasmid designated GHRH1-44 SK (Figure 2). A 685 bp fragment corresponding to a portion of the porcine  $\alpha$ -skeletal actin promoter designated SK685 was PCR-amplified from swine genomic DNA using primer designated SK-3, containing a Kpn I site (SEQ ID No. 6) and primer designated SK-4, containing a Hind III site; (SEQ ID No. 7). The PCR-amplified SK685 promoter fragment was then cloned into plasmid GHRH1-44SK digested with Kpn I and HindIII enzymes to produce a plasmid designated GHRH1-44WTSK685 (Figure 3).

5. pGHRH1-44WTSK2014

**[0083]** A plasmid containing the polynucleotide sequences encoding the 75-amino acid GHRH protein described above operatively linked to a fragment derived from the swine  $\alpha$ -skeletal actin promoter approximately 2014 bp (SEQ ID No. 8) was constructed as described below.

**[0084]** An approximately 2014 bp fragment designated SK 2014 corresponding to a portion of the porcine  $\alpha$ -skeletal actin promoter was PCR-amplified from swine genomic DNA using primer designated SK-7; containing a Kpn I site (SEQ ID No. 9) and primer designated SK-8; containing a Hind III site; (SEQ ID No. 10). The PCR-amplified SK2014 promoter fragment was then cloned into plasmid GHRH1-44SK which was digested with Kpn I and Hind III enzymes to produce a plasmid designated GHRH1-44WTSK2014 (Figure 4).

6. pGHRH1-29WTCMV

**[0085]** A plasmid containing the polynucleotide sequences encoding the signal sequence derived from human GHRH polynucleotides and encoding amino acids 1-29 of swine GHRH protein was produced as described below.

**[0086]** An approximately 189 bp DNA fragment was PCR-amplified from plasmid pGHRH-4 using primer designated GHRH-5, containing a Bam HI site; (SEQ ID No. 11) and primer designated GHRH-6, containing a Bgl II site; (SEQ ID No. 12). The PCR-amplified fragment was digested with Bam HI and Bgl II enzymes and cloned into plasmid pVR1012 (Vical, San Diego, CA) which was digested with Bam HI and Bgl II enzymes to produce a plasmid designated GHRH1-29WTCMV (SEQ ID No. 51) in which expression of the GHRH 1-29 protein is driven by CMV IE promoter/enhancer sequences.

7. pGHRH1-29YWTCMV

**[0087]** In order to produce novel variants of GHRH protein with enhanced stability to enzymatic degradation (*e.g.* DPPIV enzyme degradation) a plasmid containing polynucleotide sequences encoding the signal sequence of human GHRH and an altered version of the 1-29 porcine GHRH protein was produced. The alteration consisted of the addition of an extra tyrosine residue just preceding the first tyrosine residue of the natural porcine GHRH 1-29 sequence. This modification alters the amino terminal in such away that it is no longer recognized or cleaved by DPPIV enzyme. A plasmid containing the gene for this variant GHRH protein was produced as described below.

**[0088]** A set of overlapping oligonucleotides (SEQ ID Nos. 13-25) were synthesized, mixed, and GHRH was amplified using the PCR method. The PCR reaction resulted in the formation of a fragment of approximately 192 bp encoding amino acids 1-29 of GHRH in which nucleotides encoding a tyrosine residue were inserted immediately 5' to the coding sequence of GHR(1-29) and further containing a Bam HI site (5' end) and an Bgl II site (3' end ). The 192 bp fragment

was then digested with Bam HI and Bgl II enzymes and cloned into plasmid pVR1012 which was digested with Bam HI and Bgl II enzymes to produce plasmid designated GHRH1-29YWTCMV (SEQ ID No. 52) in which expression of GHRH1-29 (now 30) is driven by CMV IE promoter enhancer elements.

8. pGHRH1-29YWTSK685

**[0089]** A plasmid containing the 192 bp fragment described above in Section 5 under the control of the SK685 promoter fragment was produced as described below.

**[0090]** The 192 bp fragment was amplified with two primers designated p99-S1, containing a 5' end Hind III site; (SEQ ID No. 26) and p99-A214, containing a 3' end Xba I site; (SEQ ID No. 27). The PCR-amplified fragment was then digested with Hind III and Xba I enzymes and cloned into plasmid GHRH1-29 Yala1522SK685 (see below) also digested with Hind III and Xba I enzymes to produce plasmid GHRH1-29YWTSK685 (SEQ ID No. 53).

9. pGHRH1-29YWTSK2014

**[0091]** A plasmid containing the 192 bp fragment described above in Section 5 under the control of the SK2014 promoter fragment was produced as described below.

**[0092]** The 192 bp fragment was amplified with two primers designated p99-S1 containing a 5' end Hind III site; (SEQ ID No. 28) and p99-A214 containing a 3' end Xba I site; (SEQ ID No. 29). The PCR-amplified fragment was then digested with Hind III and Xba I enzymes and cloned into plasmid GHRH1-29 YAla 1522SK2014 (see below) also digested with Hind III and Xba I enzymes to produce plasmid GHRH1-29YWTSK2014 (SEQ ID No. 54).

10. pGHRH1-29YAla1522CMV

**[0093]** In order to produce novel variants of GHRH protein with enhanced stability to enzymatic degradation (*e.g.*, due to DPPIV enzyme) and enhanced potency, a plasmid containing the signal sequence of human GHRH and an altered version of the 1-29 porcine GHRH protein was produced. The alteration consisted of the addition of an extra tyrosine residue just preceding the first tyrosine residue of the natural porcine GHRH 1-29 sequence and replacement of glycine 15 and leucine 22 with alanine. These modifications alter the amino terminal end of GHRH1-29 in such way that it is no longer by recognized or cleaved by the DPP IV enzyme and the modified protein has enhanced potency relative to the 29 or the 44 amino acid GHRH protein. A plasmid containing the gene for this variant protein was produced as described below.

**[0094]** A set of overlapping oligonucleotides were synthesized (SEQ ID Nos. 30-42), mixed and amplified using the PCR method. The PCR reaction resulted in the formation of a fragment of approximately 192 bp containing a Bam HI site (5' end) and an Bgl II site (3' end) and in which an extra three nucleotides encoding for tyrosine is immediately 5' to the nucleotide sequence encoding the natural tyrosine at position 1 of the GHRH1-29 sequence. Furthermore, the alteration included replacement of the 3 nucleotides encoding glycine 15 with three nucleotides encoding alanine and replacement of three nucleotides encoding leucine 22 with three nucleotides encoding alanine. The 192 bp fragment was then digested with Bam HI and Bgl II enzymes and cloned into plasmid pVR1012 which was digested with Bam HI and Bgl II enzymes to produce plasmid designated GHRH1-29YAla 1522CMV in which expression of the variant GHRH1-29 (now 30) is driven by CMV IE promoter enhancer elements (SEQ ID No. 55).

11. pGHRH1-29YAla1522SK685

**[0095]** A plasmid containing the GHRH1-29YAla1522 fragment described above under the control of the SK685 promoter fragment was produced as described below.

**[0096]** An approximately 192 bp fragment as described above in Section 8 was PCR-amplified with primers designated p99-S1, containing a Hind III at 5' end (SEQ ID No. 26) and p99-A214 containing a Xba I site at 3' end; (SEQ ID No. 27). The PCR-amplified fragment was digested with Hind III and Xba I enzymes and cloned into plasmid *pGL3* (Promega) also digested with Hind III and Xba I to produce plasmid GHRH1-29YAla 1522SK (SEQ ID No. 56). A 685 bp fragment corresponding to a portion of the porcine  $\alpha$ -skeletal actin promoter was PCR-amplified from swine genomic DNA using primers SK-3 (Kpn I site) and SK-4 (Hind III site). This fragment was designated SK685. The PCR-amplified SK685 promoter fragment was then cloned into plasmid GHRH1-29YAla1522SK digested with KpnI and HindIII enzymes to produce a plasmid designated GHRH1-29YAla1522SK685 (SEQ ID No. 57).

12. pGHRH1-29YAla1522SK2014

**[0097]** A plasmid containing the GHRH1-29YAla1522 fragment described above under the control of the SK2014

promoter fragment was produced as described below.

**[0098]** An approximately 192 bp fragment as described above in Section 8 was PCR amplified with primers designated p99-S1 containing a Hind III at 5' end; (SEQ ID No. 26) and p99-A214 containing a Xba I site at 3' end; (SEQ ID No. 27). The PCR-amplified fragment was digested with Hind III and Xba I enzymes and cloned into plasmid *pGL3* (Promega) also digested with HindIII and Xba I to produce plasmid GHRH1-29YAla1522SK. An 2014 bp fragment corresponding to a portion of the porcine  $\alpha$ -skeletal actin promoter was PCR-amplified from swine genomic DNA using primers SK-7 containing a Kpn I site and SK-8 containing a Hind III site. This fragment was designated SK2014. The PCR-amplified SK2014 promoter fragment was then cloned into plasmid GHRH1-29YAla1522SK digested with Kpn I and Hind III enzymes to produce a plasmid designated GHRH1-29YAla1522SK2014 (SEQ ID No. 58).

#### 13. pGHRH 1-44YWTCMV

**[0099]** In order to produce novel variants of GHRH protein with enhanced stability to enzymatic degradation (*e.g.*, due to DPPIV enzyme) a plasmid containing the signal sequence of human GHRH and an altered version of the 1-44 porcine GHRH protein was produced. The alteration consisting of the addition of an extra tyrosine residue immediately 5' to the nucleotide sequence encoding the first tyrosine residue of the natural porcine GHRH 1-44 sequence. This modification will alter the amino terminal end in such away that it is no longer by recognized or cleaved by DPPIV enzyme. A plasmid containing the gene for this modified GHRH protein is produced as described below.

**[0100]** A set primers designated GHRH-1 (SEQ ID No. 61) and GHRH-3 (SEQ ID No. 65) were used in a PCR reaction amplify the human GHRH signal sequence and porcine GHRH from pGHRH1-29YWTCMV. The resulting GHRH fragment was digested with Bam HI and Bgl II, and cloned into the Bam HI site of plasmid pVR1012 (Vical, San Diego, CA) to produce the plasmid designated GHRH1-44YWTCMV (SEQ ID No. 59).

#### 14. SYNTHESIS OF GH CONSTRUCTS

**[0101]** In order to provide plasmid constructs containing GH genes suitable for treatment of growth hormone maladies or to enhance animal health and productivity, the construction of plasmids of the invention and their methods of use are described below in detail.

**[0102]** The canine GH gene was cloned into plasmids vectors suitable for the various aspects of the present invention using the following procedures. Total RNA was prepared from the pituitary gland of a dog using the RNAzol B method using reagents and procedures from Biotecx Laboratories, Houston TX. Briefly, about 0.15 mg of the tissue was homogenized in 2 ml of RNAzol B solution in a RNase-free glass homogenizer. The material was then divided into two equal halves, and RNA extracted by chloroform and ethanol precipitation. The nucleic acid pellet was dried and taken up in RNase-free water. Reverse transcription (RT) of total RNA was done in a 20 ml volume using 0.02 mg of RNA, 138 pmol of oligo #2 (SEQ ID No. 43), 1 mM MnCl<sub>2</sub>, and the recommended amounts of dNTPs and rTth enzyme from the RT-PCR kit purchased from Perkin-Elmer, Norwalk, CT. The reaction was incubated at 70°C for 11 min in a Perkin-Elmer Thermal cycler. The completed (RT) reaction was then subjected to PCR following addition of 66 pmol of oligo #1 (SEQ ID No. 44), 2.5 mM MgCl<sub>2</sub>, and chelating buffer from the RT-PCR reaction kit. The PCR conditions were as follows: 94 C, 1 min; 55 C, 1 min; and 72 C, 2 min; for 32 cycles. The 0.7 kb PCR-amplified DNA fragment obtained was cloned into plasmid pCRScript purchased from Stratagene, La Jolla, CA and used according to manufacturer's recommendations. The recombinant plasmid thus generated was termed cCG-SP. The insert fragment was partially sequenced and confirmed to contain the growth hormone ("GH") DNA sequences. cGH-SP plasmid DNA was then used as a template to PCR-amplify using oligonucleotides oligo #3 (SEQ ID No. 45) and oligo #4 (SEQ ID No. 46) using reagents from the PCR system kit from Perkin-Elmer using standard procedures and following cycling conditions: 94 C, 1 min 1 cycle; 94 C, 30 sec; 55 C, 30 sec; 72 C, 1 min; 30 cycles. The 0.7 kb PCR-amplified DNA fragment obtained was subjected to column purification (Qiagen, Chatsworth, CA), and digested with restriction enzymes EcoRV and BglII by standard protocols (Sambrook et al., 1989). The digested PCR fragment was ligated to EcoRV-BglII digested pCMV-MCS, a plasmid derivative of pCMVb (Clontech, Palo Alto, CA), engineered to contain multiple cloning sites in place of lacZ gene. The ligation product was used to transform *E. coli*, and transformants were selected for resistance to ampicillin (pCMV-MCS-enocoded marker). Transformants were analyzed by plasmid DNA preparation and restriction site analysis, and a clone of the GH DNA sequences in pCMV-MCS was isolated (termed pCGH#9). The insert sequences were completely sequenced by standard procedures to confirm presence of GH DNA sequences. The EcoRV-BglII GH fragment from pCGH#9 has also been sub-cloned into gene therapy plasmid VR1012 (obtained from Vical, San Diego, CA). This clone referred to as pC51.

#### 15. SYNTHESIS OF GH-GHRH CONSTRUCTS

**[0103]** A GH-GHRH fusion protein, comprising the carboxy terminal 20 amino acids of GH and full length wildtype



GHRH is produced. The full length GHRH gene is PCR amplified from plasmid pGHRH-4 using two primers designated GHRH-1 containing a Bgl II site (SEQ ID No. 61) and GHRH-2 containing a Bam HI site (SEQ ID No. 62). The PCR-amplified fragment is then cloned into the Bam HI site of the pVR1012 plasmid. Two complementary oligonucleotides encoding the carboxy terminal amino acids 172-191 of GH (GH-1 oligo.; SEQ ID No. 62 and GH-2 oligo.; SEQ ID No. 63) are synthesized. The GH-1 and GH-2 oligonucleotides are annealed and cloned into the Bam HI site of the pVR1012 plasmid containing the full length GHRH gene to produce pGHRH1-44WTGHpep (SEQ ID No. 60).

#### 16. IN VITRO STUDIES ASSESSING GHRH EXPRESSION LEVELS

**[0104]** In order to assess the expression level of GHRH from pGHRH-4, this plasmid or pVR1012 was transfected into C2C12 mouse myoblasts using the fugene reagent according to the manufacturer's recommendations (Boehringer Ingelheim). Supernatant harvested from transfected and non-transfected cells at various time points were assayed for the presence of GHRH using a commercially available radioimmune assay kit (Pennisula Laboratories). The results depicted in Figure 5 indicate that GHRH production could be detected 24 hours post-transfection.

#### 17. THE EFFECT OF GH PLASMID INJECTION ON SWINE GROWTH

**[0105]** In order to evaluate the effect of a single injection of plasmids containing GH gene on swine growth, experiments addressing the effect GH treatment on swine of different ages were carried out according to the experimental design described below.

#### MATERIALS & METHODS

**[0106]** Thirty six 3-week old (weaned) cross-bred (Yorkshire X landrace) pigs of mixed sex were brought into experimental barns and maintained for an acclimation period of 3 weeks. Animals were kept in pens (2/pen) according to treatment group. Animals were fed daily a non-medicated commercial pig diet ad libitum (16% protein pellet until approximately 45 Kg body weight and then a 14% protein pellet until slaughter) and fresh water was available ad libitum. Animals were randomized into one of four treatment groups (A-D; table 1) according to weight, sex and litter. Eight animals in group A were injected once with plasmids containing GH gene at 6 weeks of age. Controls (10 animals; group C) were injected with blank plasmid vector when they were also 6 weeks of age. Eight animals in group B were injected once with plasmids containing GH gene at 13 weeks of age. Controls (group D; 10 animals) were injected with blank plasmid vector when they were also 13 weeks of age. Food consumption was recorded daily for each pen and animals were weighed on two consecutive days each week until slaughter. Loin eye area and back fat were quantified at slaughter.

Table 1.

Experimental Design				
Group	Number of Animals	Plasmid dose	Age at time of injection	Weight at time of injection
A	8	4.6 mg	6 weeks	12.4
B	8	4.6 mg	13 weeks	4.2
C	10	Placebo	6 weeks	13.8
D	10	Placebo	13 weeks	41.9

#### RESULTS

**[0107]** As shown in table 2, treatment of 6 week-old pigs with plasmids encoding GH gene results in enhanced performance. This is evident by the 5% increase in weight gain and 5.1% increase in Average daily gain (ADG) achieved in GH injected animals versus placebo injected pigs. Moreover, the data shows that GH plasmid injection resulted in an improvement of 3.3 % in feed efficiency (ratio of feed consumed relative to weight gain) as well as an increase of 7.2% in loin eye area of GH plasmid injected animals.

**[0108]** The data in table 3 shows that treatment of 13 week-old pigs with plasmids encoding GH gene results in an even higher magnitude of increase in animal performance relative to age placebo injected controls than treatment of 6 week-old pigs. This is evident by the 9.5% increase in weight gain and 9.3% increase in Average daily gain (ADG) achieved in GH injected animals versus placebo injected pigs. Moreover, the data shows that GH plasmid injection resulted in an improvement of 6.7 % in feed efficiency (ratio of feed consumed relative to weight gain) as well as an

## EP 1 205 551 A1

increase of 6.8% in loin eye area of GH plasmid injected animals. Thus treatment of animals with plasmids containing GH gene results in enhanced animal growth and performance.

Table 2:

The effect of GH plasmid administration of weight gain			
Group	A	C	% Improvement
Weight at injection time (Kg)	12.4	13.8	
Weight gain <sup>a</sup>	77.7	73.8	5.0%
ADG <sup>b</sup>	.79	.75	5.1%
total feed intake/pen <sup>c</sup>	473.3	457.6	3.4%
Feed intake/pen/day <sup>d</sup>	4.8	4.7	2.1%
feed to gain <sup>e</sup>	3.03	3.13	3.3%
Loin eye area at Slaughter (Cm <sup>2</sup> )	39.51	36.83	7.2%
a→e = from time of injection to time of slaughter			

Table 3:

The effect of GH plasmid administration of weight gain			
Group	B	D	% Improvement
Weight at injection time (Kg)	42.0	41.9	N/A
Weight gain <sup>a</sup>	52.1	47.6	9.5%
ADG <sup>b</sup>	1.06	.97	9.3%
total feed intake/pen <sup>c</sup>	309.6	300.7	3.0%
Feed intake/pen/day <sup>d</sup>	6.3	6.1	3.3%
feed to gain <sup>e</sup>	3.0	3.2	6.7%
Loin eye area at Slaughter (Cm <sup>2</sup> )	41.61	38.96	6.8%
a→e = from time of injection to time of slaughter			

**[0109]** A number of references have been cited and the entire disclosures of which are incorporated herein by reference.

**[0110]** The present invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

# EP 1 205 551 A1

<110> Pfizer Products Inc.

5 <120> GROWTH HORMONE AND GROWTH HORMONE RELEASING HORMONE  
COMPOSITIONS

<130> PC10525A

10 <140>  
<141>

15 <160> 67

<170> PatentIn Ver. 2.1

20 <210> 1  
<211> 246  
<212> DNA  
<213> Artificial Sequence

25 <220>  
<223> Description of Artificial Sequence:  
oligonucleotide

30 <400> 1  
ggatccgcca ccatgccact ctgggtgttc ttctttgtga tcctcacct cagcaacagc 60  
tcccactgct cccacctcc cctttgacc ctcaggatgc ggcggtatgc agatgccatc 120  
ttcaccaaca gctaccggaa ggtgctgggc cagctgtccg cccgcaagct gctccaggac 180  
35 atcatgagca ggcagcaggg agagagaaac caagagcaag gagcaagggt gcggctttga 240  
agatct 246

40 <210> 2  
<211> 75  
<212> PRT  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence: GHRH protein

50 <400> 2  
Met Pro Leu Trp Val Phe Phe Phe Val Ile Leu Thr Leu Ser Asn Ser  
1 5 10 15  
55 Ser His Cys Ser Pro Pro Pro Pro Leu Thr Leu Arg Met Arg Arg Tyr  
20 25 30

# EP 1 205 551 A1

Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln Leu  
35 40 45

5 Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly Glu  
50 55 60

10 Arg Asn Gln Glu Gln Gly Ala Arg Val Arg Leu  
65 70 75

<210> 3

15 <211> 685

<212> DNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence:  
obligonucleotide

<400> 3

25 ggtaccatcg ctggggagct gggggagggg tcgccttctt gccctaccca ggactccggg 60  
tgcgaccgct cctctatctc tccagccac caccactoca ccaacttgga acgtctccct 120  
cctccctgga gtcgctctag agggtttggg ggtctgagta aagaaccga agtagggata 180  
cagtgtggcg gcaccttcca gagggcccg ggcagggta gaccggggcg gggcgggccg 240  
30 cggacaggtg cagccccagg cgcaggcga ctgcgcctc ccggcgagg cggtgaacct 300  
cgccccaccc cagccctcc ggggggcagc tgggcgggt cgggaggggc ccaccagccc 360  
gggagacact ccatatacgg ccaggccgc ttacctggg ctccggccag gccgctcctt 420  
ctttggctcg cacaggggac ccgggcgggg gccagggcg ctaaccggcc gggggagggg 480  
gctccagtgc ccaacaccca aatatggctc gagaagggga gcgacattcc agtgaggcgg 540  
35 ctcgggggga gaaccgcgg gctatataaa acctgagcgt ggggaccagc ggccaccgca 600  
gcggacagcg ccgagagaag cctcgcttcc ctcccgggc gaccagggcc ccagccggag 660  
agcagcaggt gtagccacca agctt 685

40 <210> 4  
<211> 30

<212> DNA

45 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

50 <400> 4

aatcccaagg ttgccaccat gccactctgg 30

55 <210> 5

<211> 30

# EP 1 205 551 A1

<212> DNA  
 <213> Artificial Sequence  
 5  
 <220>  
 <223> Description of Artificial Sequence: Primer  
 <400> 5  
 10 tattgctcta gatcaaagcc gcacccttgc 30  
 <210> 6  
 15 <211> 39  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 20 <223> Description of Artificial Sequence: Primer  
 <400> 6  
 25 cgggtaccat cgctggggga gctggggcag gggtcgcct 39  
 <210> 7  
 <211> 40  
 30 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 35 <223> Description of Artificial Sequence: Primer  
 <400> 7  
 cccgcttggt ggctacacct gctgctctcc ggctggggcc 40  
 40  
 <210> 8  
 <211> 2014  
 <212> DNA  
 45 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: SK 2014  
 50 <400> 8  
 ggtaccgcta taggagagaa aagagctgca ctgagcaccc tccttcccct ttaaattgtca 60  
 acagattagg agtcagtga tgacagcaca cctcttgcta ccttagagac caaaatttaa 120  
 gctactcccc ttaagctata gctagagtgc acctgccagt gtctttagtc ccactgatg 180  
 55 gaacaggacc caaggtattg aagatggaac atagttattc attcatcctc taatttaaaa 240  
 agctggatat gctgtacagc agaaattgac ggaacaatgt aatcaacta taacagaaga 300

# EP 1 205 551 A1

aataaaaacc tggggggaaa gaagctgact atgaaacccc aggaqctttc tacatggggc 360  
 tggactcacc aaactcttta ttttgtaatg gacttctgac attttttagga agggctgtcc 420  
 5 tgatgtgggc tatagaagag ggtttcacat gcttcttcaa gaggaccac actgtcccag 480  
 ttgctgagtc ccaccaccag atgctagtgg cagctatttg gggaacactt aggcactaca 540  
 aaaaaatgag tgattccatt ctggctcaca ccataccct gatgtacccc ttaaagcatg 600  
 tcaactgagtt catcacagaa aattgtttcc cctgtgcctt ccacaacaag gttagagctg 660  
 tccttggggc caggggaagg gggcagggag tgagaagcac caactggata acctcctctg 720  
 10 acccccactc caccttacca taagtagatc caaatccttc tagaaaatta ggaaggcata 780  
 tccccatata tcagcgatat aaatagaact gcttcagcgc tctggtagac ggtgactctc 840  
 caaggtggac tgggaggcag cctggccttg gctgggcacg gtctctctaaa tagaaagatg 900  
 aacttgttca gcctttccag aaggaaaaact gctgcccagc ctacagtgcg acgtccttgt 960  
 15 cttccatctg gaggaagcac gggtagacata tcactctagta agggcacctc tctgtttcca 1020  
 cctccaggtc gaggggtgtg acccttactt ctacgcctca agggagggac actcaacycc 1080  
 ccaaaaagac atgagggcgc tcagctcggc ccaccgcacc cgggaccgga gccgtcacc 1140  
 cccgaaattc actcccttca caagccccc aagcgcgttct ctggtgcgga ctgctccggg 1200  
 20 gccctggctt tgtgcccagc gttgtcagag ccaccgcctt gagcctgtcc ccgggagccc 1260  
 cgcgcctcct ccaccgcctc cctctctcgc cccgcggcc agttgtctgc ccgagacag 1320  
 ctgctgcgcc tcccgtgctt ggtggccctc tccggtgggg gtggggaccg acagggtcag 1380  
 cctccggat ccggggcgct ccgggtagcg gggagaagtg atcgtgggg agctggggga 1440  
 25 ggggtgcctt tctgcctta ccaggactc cgggtgcgac cgtcctcta tctctccagc 1500  
 ccaccaccac tccaccactt ggacacgtct cctcctccc tggagtctgt ctagaggggt 1560  
 tgggggtctg agtaagaac ccgaagtagg gatacagtgt ggcggcacct tccagaggcc 1620  
 ccgggcgcag ggtagaccgg ggcgggcgcg cccgcggaca ggtgcagccc caggcgagg 1680  
 cgactcgcg cctccgcgcg caggcgtga acctcgcctt acccagccc ctccggggg 1740  
 30 cagctgggccc ggtcggcgag gggccacca gccgggaga cactccatat acggccaggc 1800  
 ccgctttacc tgggtccgg ccaggccgct ccttctttgg tcagcacagg ggaccgggc 1860  
 gggggcccag gccgctaacc cgccggggga ggggctcca gtgcccaca cccaaatatg 1920  
 gctcgagaag gggagcgaca ttccagttag gcggtcggg gggagaaccc gcgggtata 1980  
 35 taaaacctga gcgtggggac cagcgccaa gctt 2014

<210> 9  
 40 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 45 <223> Description of Artificial Sequence: Primer

<400> 9  
 50 cccaagcttg gccgctggtc ccacgctca 30

<210> 10  
 <211> 38  
 55 <212> DNA  
 <213> Artificial Sequence

# EP 1 205 551 A1

<220>  
 <223> Description of Artificial Sequence: Primer  
 5  
 <400> 10  
 caggtaccgc tataggagac aaaagagtgc actgagca 38  
 10  
 <210> 11  
 <211> 46  
 <212> DNA  
 <213> Artificial Sequence  
 15  
 <220>  
 <223> Description of Artificial Sequence: Primer  
 20  
 <400> 11  
 agatatcccg gccgctctag accaggcccc tggatccgcc accatg 46  
 25  
 <210> 12  
 <211> 44  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <223> Description of Artificial Sequence: Primer  
 35  
 <400> 12  
 gaagatctct acctgctcat gatgtcctgg agcagcttgc gggc 44  
 40  
 <210> 13  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 45  
 <220>  
 <223> Description of Artificial Sequence: Primer  
 50  
 <400> 13  
 gtcattccga gattcggata 20  
 55  
 <210> 14  
 <211> 40  
 <212> DNA  
 <213> Artificial Sequence

EP 1 205 551 A1

<220>  
<223> Description of Artificial Sequence: Primer

5 <400> 14  
gtcattccga gattcggata cacaggatcc gccaccatcc 40

10 <210> 15  
<211> 40  
<212> DNA  
<213> Artificial Sequence

15 <220>  
<223> Description of Artificial Sequence: Primer

20 <400> 15  
cactctgggt gttcttcttt gtgatctca cctcagcaa 40

25 <210> 16  
<211> 40  
<212> DNA  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence: Primer

35 <400> 16  
cagctccac tgetcccccac ctcccccttt gaccctcagg 40

40 <210> 17  
<211> 40  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence: Primer

50 <400> 17  
atgcggcgggt attatgcaga tgccatcttc accaacagct 40

55 <210> 18  
<211> 40  
<212> DNA  
<213> Artificial Sequence



# EP 1 205 551 A1

<220>  
 <223> Description of Artificial Sequence: Primer  
 5  
 <400> 18  
 accggaaggt gctgggccag ctgtccgccc gcaagctcct 40  
 10  
 <210> 19  
 <211> 40  
 <212> DNA  
 <213> Artificial Sequence  
 15  
 <220>  
 <223> Description of Artificial Sequence: Primer  
 20  
 <400> 19  
 ccaggacatc atgagcaggt agagatctga taagcggtat 40  
 25  
 <210> 20  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <223> Description of Artificial Sequence: Primer  
 <400> 20  
 35 ataacgotta tcagatctct 20  
 40  
 <210> 21  
 <211> 40  
 <212> DNA  
 <213> Artificial Sequence  
 45  
 <220>  
 <223> Description of Artificial Sequence: Primer  
 <400> 21  
 50 acctgctcat gatgtcctgg accagcttgc gggcggacag 40  
 55  
 <210> 22  
 <211> 40  
 <212> DNA  
 <213> Artificial Sequence

EP 1 205 551 A1

<220>  
<223> Description of Artificial Sequence: Primer

5  
<400> 22  
ctggcccagc accttcggt agctgttggg gaagatggca 40

10  
<210> 23  
<211> 40  
<212> DNA  
<213> Artificial Sequence

15  
<220>  
<223> Description of Artificial Sequence: Primer

20  
<400> 23  
tctgcataat accgccgcat cctgagggtc aaacccccag 40

25  
<210> 24  
<211> 40  
<212> DNA  
<213> Artificial Sequence

30  
<220>  
<223> Description of Artificial Sequence: Primer

35  
<400> 24  
gtggggagca gtgggagctg ttgctgaggg tgaggatcac 40

40  
<210> 25  
<211> 40  
<212> DNA  
<213> Artificial Sequence

45  
<220>  
<223> Description of Artificial Sequence: Primer

50  
<400> 25  
gtggggagca gtgggagctg ttgctgaggg tcaggatcac 40

55  
<210> 26  
<211> 30  
<212> DNA  
<213> Artificial Sequence

EP 1 205 551 A1

5  
    <220>  
    <223> Description of Artificial Sequence: Primer  
  
    <400> 26  
    gagctcaagc ttgccaccat gccactctgg 30  
  
10  
    <210> 27  
    <211> 28  
    <212> DNA  
    <213> Artificial Sequence  
  
15  
    <220>  
    <223> Description of Artificial Sequence: Primer  
  
20  
    <400> 27  
    aagatctaga ctacctgctc atgatgctc 28  
  
25  
    <210> 28  
    <211> 30  
    <212> DNA  
    <213> Artificial Sequence  
  
30  
    <220>  
    <223> Description of Artificial Sequence: Primer  
  
35  
    <400> 28  
    gagctcaagc ttgccaccat gccactctgg 30  
  
40  
    <210> 29  
    <211> 28  
    <212> DNA  
    <213> Artificial Sequence  
  
45  
    <220>  
    <223> Description of Artificial Sequence: Primer  
  
50  
    <400> 29  
    aagatctaga ctacctgctc atgatgctc 28  
  
55  
    <210> 30  
    <211> 20  
    <212> DNA  
    <213> Artificial Sequence

EP 1 205 551 A1

<220>  
<223> Description of Artificial Sequence: Primer

5 <400> 30  
gtcattccga gattcggata 20

10 <210> 31  
<211> 40  
<212> DNA  
<213> Artificial Sequence

15 <220>  
<223> Description of Artificial Sequence: Primer

20 <400> 31  
gtcattccga gattcggata cacaggatcc gccaccatcc 40

25 <210> 32  
<211> 40  
<212> DNA  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence: Primer

35 <400> 32  
cactctgggt gttcttcttt gtgatcctca ccctcagcaa 40

40 <210> 33  
<211> 39  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence: Primer

50 <400> 33  
cagctccact gctccccacc tccccctttg accctcagg 39

55 <210> 34  
<211> 40  
<212> DNA  
<213> Artificial Sequence

EP 1 205 551 A1

<220>  
<223> Description of Artificial Sequence: Primer  
5  
<400> 34  
atgcggcgggt attatgcaga tcccatcttc accaacagct 40  
10  
<210> 35  
<211> 40  
<212> DNA  
<213> Artificial Sequence  
15  
<220>  
<223> Description of Artificial Sequence: Primer  
20  
<400> 35  
accggaaggt gctggcccag ctgtccgccc gcaaggccct 40  
25  
<210> 36  
<211> 40  
<212> DNA  
<213> Artificial Sequence  
30  
<220>  
<223> Description of Artificial Sequence: Primer  
35  
<400> 36  
ccaggacatc atgagcaggt agagatctga taagcggttat 40  
40  
<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
45  
<220>  
<223> Description of Artificial Sequence: Primer  
50  
<400> 37  
ataacgctta tcagatctct 20  
55  
<210> 38  
<211> 40  
<212> DNA  
<213> Artificial Sequence

EP 1 205 551 A1

<220>  
<223> Description of Artificial Sequence: Primer

5 <400> 38  
acctgctcat gatgtcctgg agggccttgc gggcccacag 40

10 <210> 39  
<211> 40  
<212> DNA  
<213> Artificial Sequence

15 <220>  
<223> Description of Artificial Sequence: Primer

20 <400> 39  
ctgggccagc accttcoggt acctgttggt gaagatggca 40

25 <210> 40  
<211> 40  
<212> DNA  
<213> Artificial Sequence .

30 <220>  
<223> Description of Artificial Sequence: Primer

35 <400> 40  
tctccataat accgccgcat cctgagggtc aaagggggag 40

40 <210> 41  
<211> 40  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence: Primer

50 <400> 41  
gtggggagca gtgggagctg ttgctgaggg tgaggatcac 40

55 <210> 42  
<211> 40  
<212> DNA  
<213> Artificial Sequence

EP 1 205 551 A1

<220>  
<223> Description of Artificial Sequence: Primer

5  
<400> 42  
gtggggagca gtgggagctc ttgctgaggg tgaggatcac 40

10  
<210> 43  
<211> 25  
<212> DNA  
<213> Artificial Sequence

15  
<220>  
<223> Description of Artificial Sequence: Primer

20  
<400> 43  
ctagaaggca cagctgcttt ccacg 25

25  
<210> 44  
<211> 25  
<212> DNA  
<213> Artificial Sequence

30  
<220>  
<223> Description of Artificial Sequence: Primer

35  
<400> 44  
atggctgcag gcccccgac ctctg 25

40  
<210> 45  
<211> 27  
<212> DNA  
<213> Artificial Sequence

45  
<220>  
<223> Description of Artificial Sequence: Primer

50  
<400> 45  
aaagatatca tggctgcagg cccccgg 27

55  
<210> 46  
<211> 27  
<212> DNA  
<213> Artificial Sequence

# EP 1 205 551 A1

<220>

<223> Description of Artificial Sequence: Primer

5

<400> 46

aaaagatctc tagaaggcac agctgct

27

10

<210> 47

<211> 5185

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence: pGHRH-4  
construct

20

<400> 47

```

gctgtgccct ctagttgcca gccatctggt gtttgcacct ccccggtgcc ttccttgacc 60
ctggaagggt ccaactccac tgtcctttcc taataaaatg aggaaattgc atcgcatgtt 120
ctgagtaggt gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat 180
25 tgggaagaca atagcaggca tgcctgggat gcggtgggct ctatgggtac ccagggtgctg 240
aagaattgac ccggttcctc ctgggccaga aagaagcagg cacatccctc tctctgtgac 300
acaccctgtc cagccctctg gttcttagtt ccagcccccac tcataggaca ctcatagctc 360
aggagggtct cgccttcaat cccacccgct aaagtacttg gacgggtctc tccctccctc 420
30 atcagcccac caaaccaaac ctgacctcca agagtgggaa gaaattaaag caagataggc 480
tattaagtgc agaggagag aaaatgctc caacatgtga ggaagtaatg agagaaatca 540
tagaatttct tccgcttctc cgtcactga ctcgctgcgc tcggctcgtc ggctgcggcg 600
agcgggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc 660
aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa agggcgcggt 720
35 gctggcggtt ttcctatagg tccgcccccc tgacgagcat caaaaaatc gacgtcaag 780
tcagagggtg cgaacccga caggactata aagataccag gcgtttcccc ctggaagctc 840
cctcgtgcgc tctcctgttc cgacctgcc gcttaccgga tacctgtccg cctttctccc 900
ttcgggaagc gtggcgcttt ctcatagctc acgtgttagg tatctcagtt cgggtgtaggt 960
40 cgttcgctcc aagctgggct gtgtgcacga acccccgtt cagcccgacc gctgcgcctt 1020
atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc 1080
agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 1140
gtggtggcct aactacggct acactagaag aacagtattt ggtatctgcg ctctgctgaa 1200
45 gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg 1260
tagcgggtgt tttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 1320
agatcctttg atcttttcta cggggtctga cgtcagtg aacgaaaaact caggttaagg 1380
gattttggct atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg 1440
aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgctt 1500
50 aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag ttgcctgact 1560
cggggggggg gggcgctgag gtctgcctcg tgaagaagg gttgctgact cataccaggc 1620
ctgaatcgcc ccatcatcca gccagaaagt gagggagcca cggttgatga gagctttgtt 1680
gtaggtggac cagttggtga ttttgaactt ttgctttgcc acggaacggg ctgcgttgtc 1740
55 ggggaagatg gtgatctgat ccttcaactc agcaaaagtt cgatttatc acaaaagccg 1800
ccgtcccgct aagtcagcgt aatgctctgc cagtgttaca accaattaac caattctgat 1860

```



EP 1 205 551 A1

tagaaaaact catcgagcat caaatgaaac tgcaatttat tcatatcagg attatcaata 1920  
 ccatatTTTT gaaaaagccg tttctgtaat gaaggagaaa actcaccgag gcagttccat 1980  
 5 aggatggcaa gatcctggta tcggtctgcg attccgactc gtccaacatc aatacaacct 2040  
 attaatTTCC cctcgtcaaa aataaggtta tcaagtgaga aatcaccatg agtgacgact 2100  
 gaatccggtg agaattggcaa aagcttatgc atttctTTCC agacttgTTC aacaggccag 2160  
 ccattacgct cgtcatcaaa atcaactcga tcaaccaaac cgttatTcat tcgtgattgc 2220  
 gcctgagcga gacgaaatac gcgatcgctg ttaaaaggac aattacaaac aggaatcgaa 2280  
 10 tgcaaccggc gcaggaacac tgccagcgca tcaacaatat ttTcacctga atcaggatat 2340  
 tcttctaata cctggaatgc tgttttcccg gggatcgcg tggtagtaa ccatgcatca 2400  
 tcaggagtac ggataaaatg cttgatggTc ggaagaggca taaattccgt cagccagttt 2460  
 agtctgacca totcatctgt aacatcattg gcaacgctac ctttgccatg ttTcagaaac 2520  
 15 aactctggcg catcgggctt cccatataat cgatagattg tcgcacctga ttgcccagaca 2580  
 ttatcgcgag cccatttata cccatataaa tcagcatcca tgttggaatt taatcgcggc 2640  
 ctogagcaag acgtttcccg ttgaatatgg ctcaatacac cccttgTatt actgtttatg 2700  
 taagcagaca gttttattgt tcatgatgat atatttttat cttgtgcaat gtaacatcag 2760  
 20 agattttgag acacaacgtg gctttccccc ccccccatt attgaagcat ttatcagggt 2820  
 tattgtctca tgagcggata catatttgaa tgtattttaga aaaataaaca aatagggggt 2880  
 ccgcgacat ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 2940  
 ttaacctata aaaataggcg tatcacgagg ccctttcgtc ctcgcgcgTt tcggtgatga 3000  
 cggtgaaaaac ctctgacaca tgcagctccc ggagacggTc acagcttgTc tgtaagcgga 3060  
 25 tgccgggagc agacaagccc gtcaggggcg gtcagcgggt gttggcgggt gtcggggctg 3120  
 gcttaactat gcggcacatc agcagattgt actgagagtG caccatatgc ggtgtgaaat 3180  
 accgcacaga tgcgtaagga gaaaataccg catcagattg gctattggcc attgcatacg 3240  
 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgccatgt 3300  
 30 tgacattgat tattgactag ttattaatag taatcaatta cggggTcatt agttcatagc 3360  
 ccatatatgg agttcccggt tacataactt acggtaaatg gcccgctggt ctgaccgcc 3420  
 aacgaccccc gccattgac gtcaataatg acgtatgtTc ccatagtaac gccaataggg 3480  
 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt ggcagtacat 3540  
 35 caagtgtatc atatgccaag tacgccccct attgacgtca atgacggtaa atggcccgcc 3600  
 tggcattatg ccagtagac gaccttatgg gactttccta cttggcagta catctacgta 3660  
 ttagtcacg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag 3720  
 cggtttgact cacggggatt tccaagtctc caccocattg acgtcaatgg gagtttgTtt 3780  
 tggcaccaaaa atcaacggga ctttccaaaa tgtcgttaaca actccgcccc attgacgcaa 3840  
 40 atgggcggta ggcgtgtacg gtgggaggTc tatataagca gagctcgTtt agtgaaccgt 3900  
 cagatcgctt ggagacgcca tccacgctgt tttgacctcc atagaagaca ccgggaccga 3960  
 tccagcctcc gcggcgggga acggtgcatt ggaacgcgga ttccccgtgc caagagtgc 4020  
 gtaagtaccg cctatagact ctataggcac acccctttgg ctcttatgca tgcataactg 4080  
 45 tttttggctt ggggcctata caccoccgct tcttatgct ataggTgatg gtatagctta 4140  
 gcctataggT gtgggttatt gaccattatt gaccactccc ctattggtga cgatactttc 4200  
 cattaactaT ccataacatg gctctttgcc acaactatct ctattggota tatgccaata 4260  
 ctctgtcctt cagagactga cacggactct gtatttttac aggatggggT cccatttatt 4320  
 50 atttacaatT tcacatatac aacaacgcg tcccccgTgc ccgcagtttt tattaacat 4380  
 agcgtgggat ctccacgoga atctcgggta cgtgttccgg acatgggTc ttctccggta 4440  
 gggcgggagc ttccacatcc gagccctggT cccatgcctc cagcggctca tggTcgctcg 4500  
 gcagctcctt gtcctaaca gtggaggcca gacttaggca cagcacaatg cccaccacca 4560  
 ccagtgtgc gcacaaggcc gtggcggtag ggtatgtgc tgaaaatgag cgtggagatt 4620  
 55 gggctcgcaT ggtgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca 4680  
 gctgagttgT tgtattctga taagagtccag aggtaaactcc cgttcgggtg ctgttaacgg 4740

# EP 1 205 551 A1

5 tggagggcag tgtagtctga gcagtactcg ttgctgccgc gcgcgccacc agacataata 4800  
 gctgacagac taacagactg ttcttttcca tgggtctttt ctgcagtcac cgtcgtcgac 4860  
 acgtgtgatc agatatcgcg gccgctctag accaggcgcc tggatccgcc accatgccac 4920  
 10 tctgggtggtt cttctttgtg atcctcacc ctagcaacag ctcccaactgc tccccacctc 4980  
 cccctttgac cctcaggatg cggcgggtatg cagatgccat cttcaccaac agctaccgga 5040  
 aggtgctggg ccagctgtcc gcccgcaagc tgctccagga catcatgagc aggcagcagg 5100  
 gagagagaaa ccaagagcaa ggagcaaggg tgccgctttg aagatcttag tagtagtagg 5160  
 15 cggccgctct agaggatcca gatct 5185

<210> 48

15 <211> 3369

<212> DNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: pGHRH1-44SK  
 construct

<400> 48

25 ggtaaccgagc tcttacgcgt gctagccgg gctcgagatc tgcgatctaa gtaagcttgc 60  
 caccatgccca ctctgggtgt tcttctttgt gatcctcacc ctcagcaaca gctcccaactg 120  
 ctccccacct cccctttga cctcaggat gcggcggtat gcagatgccca tcttcaccaa 180  
 cagctaccgg aaggtgctgg gccagctgtc gcgccgcaag ctgctccagg acatcatgag 240  
 30 caggcagcag ggagagagaa accaagagca aggagcaagg gtgcggcttt gatctagagt 300  
 cggggcgggc ggccgcttcg agcagacatg ataagataca ttgatgagtt tggacaaacc 360  
 acaactagaa tgcagtga aaatgcttt atttgtaaa tttgtgatgc tattgcttta 420  
 tttgtaacca ttataagctg caataaaca gttacaaca acaattgcat tcattttatg 480  
 tttcagggtc agggggagggt gtgggagggt ttttaaagca agtaaaacct ctacaaatgt 540  
 35 ggtaaaatcg ataaggatcc gtcgaccgat gcccttgaga gccttcaacc cagtcagctc 600  
 cttccgggtg gcgcggggca tgactatcgt gcgcgcactt atgactgtct tctttatcat 660  
 gcaactcgta ggacagggtc cggcagcgct ctccgccttc ctgctcact gactcgctgc 720  
 gctcggtcgt tcggctgcgg cgagcggtat cagctcactc aaaggcggtg atacggttat 780  
 40 ccacagaatc aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca 840  
 ggaaccgtaa aaaggccggc ttgctggcgt ttttccatag gctccgcccc cctgacgagc 900  
 atcacaaaaa tcgacgctca agtcagaggt gcgaaaccc gacaggacta taaagatacc 960  
 aggcgtttcc ccctggaagc tcctcgtgc gctctcctgt tccgacctg ccgcttaccg 1020  
 45 gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct ttctcaatgc tcacgtgtga 1080  
 ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg 1140  
 ttcagcccgga ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaaagc 1200  
 accacttata gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag 1260  
 gcgggtgctac agagtctctg aagtgggtgc ctaactacgg ctacactaga aggacagtat 1320  
 50 ttggtatctg cgtctgctg aagccagtta ccttcggaaa aagagttggg agctcttgat 1380  
 ccggcaaaaca aaccaccgct ggtagcgggt gtttttttgt ttgcaagcag cagattacgc 1440  
 gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt 1500  
 ggaacgaaaa ctacagttaa gggatttttg tcatgagatt atcaaaaagg atcttcacct 1560  
 55 agatcctttt aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagttaaactt 1620  
 ggtctgacag ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc 1680

# EP 1 205 551 A1

gttcattccat agttgactga ctccccgtcg tgtagataac tacgatacgg gagggccttac 1740  
catctggccc cagtgtctga atgataccgc gagacccacg ctacccggct ccagatttat 1800  
5 cagcaataaa ccagccagcc ggaagggccg agcgacagaag tggctcctgca actttatccg 1860  
cctccatcca gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata 1920  
gtttgcgcaa cgttggtgcc attgctacag gcacgtggt gtcacgctcg tcgtttggta 1980  
tggcttcatt cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt 2040  
gcaaaaaagc ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag 2100  
10 tgttatcact catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa 2160  
gatgcttttc tgtgactggt gactactcaa ccaagtcatt ctgagaatag tgtatgcggc 2220  
gaccgagttg ctcttgcccg gcgtcaatac ggataatac cgcgccacat agcagaactt 2280  
taaaagtgtc catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc 2340  
15 tgttgagatc cagttcgatg taaccactc gtgcacccaa ctgatcttca gcacttttta 2400  
ctttcaccag cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaaggga 2460  
taaggcgac acggaatgt tgaatactca tactcttcct ttttcaatat tattgaagca 2520  
tttatcaggg ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac 2580  
20 aaataggggt tccgcgcaca tttcccgaa aagtgcacc tgacgcgcc tgtagcggcg 2640  
cattaagcgc gcgggtgtg gtggttacgc gcagcgtgac cgtacactt gccagcgccc 2700  
tagcgcgcc tcctttcgct ttcttccctt cctttctcgc cagtttcgcc ggttttcccc 2760  
gtcaagctct aaatcgggg ctccctttag ggttccgatt tagtgcttta cggcacctcg 2820  
accccaaaaa acttgattag ggtgatggtt cactagtggt gccatcgccc tgatagacgg 2880  
25 tttttcgccc tttagcgttg gactccacgt tctttaatag tggactcttg ttccaaactg 2940  
gaacaacact caaccctatc tcggtctatt cttttgattt ataagggtt ttgccgattt 3000  
cggcctattg gttaaaaaat gagctgattt aacaaaaatt taacgcgaat tttaacaaaa 3060  
tattaacgtt tacaatttcc cattogccat tcaggctcgc caactgttg gaaggcgat 3120  
30 cgggtcgggc ctcttcgcta ttacgccagc ccaagctacc atgataagta agtaatatta 3180  
aggtacggga ggtacttgga gcggccgcaa taaaatatct ttattttcat tacatctgtg 3240  
tgttggtttt ttgtgtgaat cgatagtact aacatacgt ctccatcaaa acaaaacgaa 3300  
acaaaacaaa ctagcaaaat aggtgttccc cagtgcaggt gcaggtgcc gaacatttct 3360  
35 ctatcgata 3369

<210> 49

<211> 3976

40 <212> DNA

<213> Artificial Sequence

<220>

45 <223> Description of Artificial Sequence:

pGHRH1-44WTSK685 construct

<400> 49

50 ggtaccatcg ctggggagct gggggagggg tcgccttcct gccctacca ggactccggg 60  
tgcgaccgct cctctatctc tccagccac caccactcca ccacttgac acgtctccct 120  
cctccctgga gtcgctctag agggtttggg ggtctgagta aagaaccga agtagggata 180  
cagtgtggcg gcaccttcca gagggcccg gcgcagggt gaccggggcg gggcgccc 240  
cggacaggtg cagccccagg cgcaggcgca ctgcgcctc ccggcgcagg cgtgaacct 300  
55 cgccccacc cagccctcc ggggggcagc tgggcgggt cgggagggg ccaccagccc 360  
gggagacact ccatatacgg ccaggccgc tttacctgg ctccggccag gccgtcctt 420

EP 1 205 551 A1

ctttggtcag cacaggggac cggggcgggg gccagggcc ctaaccggcc gggggagggg 480  
 gctccagtg ccaacaccca aatattggctc gagaagggga gcgacattcc agtgaggcgg 540  
 5 ctcggggggga gaacccgcgg gctatataaa acctgagcgt ggggaccagc ggccaccgca 600  
 gcggacagcg ccgagagaag cctcgttcc ctcccgcggc gaccagggcc ccagccggag 660  
 agcagcaggt gtagccacca agcttgcac catgccaactc tgggtgttct tctttgtgat 720  
 cctcaccctc agcaacagct cccactgctc cccacctccc cctttgaccc tcaggatgcg 780  
 gcggtatgca gatgccatct tcaccaacag ctaccggaag gtgctgggccc agctgtccgc 840  
 10 ccgcaagctg ctccaggaca tcattgagcag gcagcaggga gagagaaacc aagagcaagg 900  
 agcaaggggt cggttttgat cttagctcgg ggccggcggc cgcttcgagc agacatgata 960  
 agatacattg atgagtttg acaaaccaca actagaatgc agtgaaaaaa atgctttatt 1020  
 tgtgaaatgt gtgatgctat tgctttattt gtaaccatta taagctgcaa taaacaagtt 1080  
 15 aacaacaaca attgcattca tttttatgtt caggttcagg gggaggtgtg ggaggttttt 1140  
 taaagcaagt aaaacctcta caaatgtggt aaaatcgata aggatccgct gaccgatgcc 1200  
 cttgagagcc ttcaaccag tcagctcctt ccggtgggccc cggggcatga ctatcgctgc 1260  
 cgcacttatg actgtcttct ttatcatgca actcgttaga cagggtgccg cagcgtctct 1320  
 20 ccgcttctc gctcactgac tcgctgcgct cggtcgttcg gctgcggcga gcggtatcag 1380  
 ctcactcaaa gccggtaata cggttatcca cagaatcagg ggataacgca ggaaagaaca 1440  
 tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa ggccgcgttg ctggcgcttt 1500  
 tccataggct ccgccccct gacgagcacc aaaaaatcg acgctcaagt cagaggtggc 1560  
 gaaaccggac aggactataa agataaccag cgtttccccc tggaagctcc ctctgctgct 1620  
 25 ctctgttcc gacctgccc cttaccggat acctgtccgc ctttctccct tcgggaagcg 1680  
 tggcgcttcc tcaatgtca cgtgttaggt atctcagttc ggtgtaggtc gttcgtcca 1740  
 agctgggctg tgtgcacgaa cccccgttc agcccgaccg ctgcgcctta tccggtaact 1800  
 atcgtcttga gtccaaaccg gtaagacacg acttatccc actggcagca gccactggt 1860  
 30 acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcttgaag tgggtggcta 1920  
 actacggcta cactagaagg acagtatttg gtatctgcgc tctgctgaag ccagttacct 1980  
 tcggaaaaag agttggtagc tcttgatccc gcaaaaaac caccgctggt agcgggtggt 2040  
 tttttgtttg caagcagcag attacgcgca gaaaaaaagg atctcaagaa gatccttga 2100  
 tcttttctac ggggtctgac gctcagtgga acgaaaactc acgttaaggg attttggta 2160  
 35 tgagattatc aaaaaggatc ttcacctaga tctttttaa ttaaaaatga agttttaaat 2220  
 caatctaaag tatatatgag taaacttggt ctgacagtta ccaatgctta atcagttagg 2280  
 cacctatctc agcgtatctg ctatttcgtt catccatagt tgctgactc cccgtcgtg 2340  
 agataactac gatacgggag ggcttaccat ctggccccag tgctgcaatg ataccgcgag 2400  
 40 acccagctc accggtcca gatttatcag caataaacca gccagccgga agggccgagc 2460  
 gcagaagtgg tctgcaact ttatccgct ccatccagtc tattaattgt tgcggggaag 2520  
 cttagtaag tagttcgcca gttaatagtt tgcgcaacgt tgttgccatt gctacaggca 2580  
 tcgtggtgct acgctcgtcg tttggtatgg ctccattcag ctccggttcc caacgatcaa 2640  
 45 ggcgagttac atgatcccc atgltgtgca aaaaagcgg tagctccttc ggtcctccga 2700  
 tcgttgtcag aagtaagttg gccgcagtg tatcactcat ggttatggca gcaactgata 2760  
 attctcttac tgtcatgcca tccgtaagat gcttttctgt gactggtgag tactcaacca 2820  
 agtcattctg agaatagtg atgcggcgac cgagttgctc ttgcccggcg tcaatacggg 2880  
 ataataccgc gccacatagc agaactttaa aagtgtcat cattgaaaa cgttcttcgg 2940  
 50 ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag ttcatgtaa cccactcgtg 3000  
 caccactg atcttcagca tcttttactt tcaccagcgt ttctgggtga gcaaaaacag 3060  
 gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatgttga atactcatac 3120  
 tcttctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg agcggatata 3180  
 55 tatttgaatg tatttagaaa aataaacaat taggggttcc gcgcacattt cccgaaaaag 3240  
 tgccacotga cgcgcctgt agcggcgcat taagcggcg ggtgtggtg gttacgcgca 3300

# EP 1 205 551 A1

gcgtgaccgc tacacttgcc agcgccctag cgcgcgctcc ttctgctttc ttcccttccct 3360  
 ttctcgccac gtctgcgggc ttcccccgtc aagctctaaa tcggggggctc ccttttaggg 3420  
 tccgatttag tgcttttacgg cacctcgacc ccaaaaaact tgatttaggg 3480  
 5 gtagtggggc atcgccctga tagacgggtt ttgcgccttt gacgttggag tccacgttct 3540  
 ttaatagtgg actcttggtc caaactggaa caacactcaa ccctatctcg gtctattctt 3600  
 ttgatttata agggattttg ccgatttcgg cctattgggt aaaaaatgag ctgatttaac 3660  
 aaaaatttaa cgcgaatttt aacaaaatat taacgtttac aatttcccat tcgccattca 3720  
 10 ggctgcgcaa ctggtgggaa gggcgatcgg tgcgggcctc ttctgtatta cgccagccca 3780  
 agctaccatg ataagtaagt aatattaagg tacgggaggt acttgagcgc gccgcaataa 3840  
 aatatcttta ttttcattac atctgtgtgt tggttttttg tgtgaatcga tagtactaac 3900  
 ataogctctc catcaaaaca aaacgaaaca aaacaaacta gcaaaatagg ctgtccccag 3960  
 15 tgcaagtgcg ggtgcc 3976

<210> 50

<211> 5325

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

pGHRH1-44WTSK2014 construct

<400> 50

30 ggtaccgcta taggagagaa aagagctgca ctgagcacc ccttccccct ttaaattgtca 60  
 acagattagg agtcagtga tgacagcaca cctcttgcta ccttagagac caaaatttaa 120  
 gctactcccc ttaagctata gctagagtgc acctgccagt gtcttttagtc ccactgatg 180  
 gaacaggacc caaggtattg aagatggaac atagtatttc attcatcctc taatttaaaa 240  
 agctggatat gctgtacagc agaaattgac ggaacaatgt aaatcaacta taacagaaga 300  
 35 aataaaaaacc tggggggaaa gaagctgact atgaaacccc aggagcttcc tacatggggc 360  
 tggactcacc aaactcttta ttttgtaatg gacttctgac attttttagga agggctgtcc 420  
 tgatgtgggc tatagaagag ggtttccat gcttcttcaa gaggaccac actgtcccag 480  
 ttgctgagtc ccaccaccag atgctagtgg cagctatttg gggaacactt aggcactaca 540  
 40 aaaaaatgag tgattccatt ctggctcaca ccatatccct gatgtacccc ttaaagcatg 600  
 tcaactgagtt catcacagaa aattgtttcc cctgtgcctt ccacaacaag gtttagagctg 660  
 tccctggggc cagggaagg gggcaggag tgagaagcac caactggata acctcctctg 720  
 acccccactc caccttaoca taagtagatc caaatccttc tagaaaatta ggaaggcata 780  
 tccccatata tcagcgatat aaatagaact gcttcagcgc tctggtagac ggtgactctc 840  
 45 caaggtggac tgggaggcag cctggccttg gctgggcac gtcctctaaa tagaaagatg 900  
 aacttggtca gcctttccag aaggaaaact gctgccagc ctacagtgc acgtccttgt 960  
 ctccatctg gaggaagcac ggtgacata tcacttagta agggcacctc tctgtttcca 1020  
 cctccaggtc gaggggtgtg accttactt ctcagcctca agggaggag actcaacccc 1080  
 50 ccaaaaagac atgagggcgc tcagctcggc ccaccgcacc ccggaccgga gccgtcacc 1140  
 ccgaaatc actcccttca caagcccca agcgcgttct ctggtgcgga ctgctccggg 1200  
 gccctggctt tgtgccagc gttgtcagag ccaccgccct gagcctgtcc ccgggagccc 1260  
 cgcgcctct cccaccgctc cgtctctcgc ccccggggc agttgtctgc ccgagacag 1320  
 55 ctgcgcgcc tcccgtgccc ggtggccctc tccggtggg gtggggaccg acagggtcag 1380  
 cctccggat ccggggcgct ccgggtagcg gggagaagtg atcgctggg agctggggga 1440

EP 1 205 551 A1

5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55

ggggtcgctt tectgccta cccaggactc cgggtgcgac cgctcctcta tctctccagc 1500  
 ccaccaccac tccaccactt ggacacgtct ccctcctccc tggagtcgct ctagaggggtt 1560  
 tgggggtctg agtaaagaac ccgaagttag gatacagtgt ggccggcacct tccagaggcc 1620  
 ccgggcgag ggtagaccgg ggccggggcg cccggcgaca ggtgcagccc caggcgagcag 1680  
 cgcactcgcg cctcccgcg caggcggtga acctcgcccc accccagccc ctccgggggg 1740  
 cagctgggccc gggtcgggag gggcccacca gcccgggaga cactccatat acggccaggc 1800  
 ccgctttacc tgggtccgg ccaggccgct ccttctttgg tcagcacagg ggaccggggc 1860  
 gggggcccag gccgctaacc cgcgggggga gggggctcca gtgcccaca cccaaatatg 1920  
 gctcgagaag gggagcgaca ttccagttag gcggctcggg gggagaaccc gcgggctata 1980  
 taaaacctga gcgtggggac cagcgcccaa gcttgccacc atgccactct ggggtgttctt 2040  
 ctttgtgato ctccacctca gcaacagctc ccactgctcc ccacctcccc ctttgacctt 2100  
 caggatgcgg cggtatgcag atgccatctt caccaacagc taccggaagg tgctggggcca 2160  
 gctgtccgcc cgcaagctgc tccaggacat catgagcagg cagcaggagg agagaaacca 2220  
 agagcaagga gcaagggtgc ggctttgato tagagtcggg gcggccggcc gcttcgagca 2280  
 gacatgataa gatacattga tgagtttga caaaccacaa ctagaatgca gtgaaaaaaaa 2340  
 tgctttatct gtgaaatttg tgatgctatt gctttatctg taaccattat aagctgcaat 2400  
 aaacaagtta acaacaacaa ttgcattcat tttatgtttc aggttcaggg ggaggtgtgg 2460  
 gaggtttttt aaagcaagta aaacctctac aaatgtggta aaatcgataa ggatccgtcg 2520  
 accgatgccc ttgagagcct tcaaccagct cagctccttc cggtgggcgc ggggcatgac 2580  
 tatcgtcgcc gcacttatga ctgtcttctt tatcatgcaa ctcgtaggac aggtgccggc 2640  
 agcgtctctc cgcttctctg ctcaactgact cgtcgcgctc ggctgttcgg ctgcggcgag 2700  
 cggtatcagc tcaactcaag gcggtaatac ggttatccac agaatcaggg gataacgcag 2760  
 gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc 2820  
 tggcgttttt ccataggctc cgcctccctg acgagcatca caaaaatcga cgctcaagt 2880  
 agaggtggcg aaacccgaca ggaactataa gataccaggc gtttccctcc ggaagctccc 2940  
 tcgtgcgctc tctgttccg acctgcccgc ttaccggata cctgtccgcc tttctccctt 3000  
 cgggaagcgt ggccgtttct caatgctcac gctgtaggta tctcagttcg gtgtaggtcg 3060  
 ttgcgtccaa gctgggctgt gtgcacgaac ccccggtca gcccgaccgc tgcgccttat 3120  
 ccggtaacta tcgtcttgag tccaaccgg taagacacga cttatcgcca ctggcagcag 3180  
 ccaactggtta caggattagc agagcgaggt atgtaggcgg tgctacagag ttcttgaaat 3240  
 ggtggcctaa ctacggctac actagaagga cagtatttgg tatctgcgct ctgctgaagc 3300  
 cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaacc accgctggta 3360  
 gcgggtggtt ttttgtttgc aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag 3420  
 atcctttgat cttttctacg gggcttgacg ctcaagtggaa cgaaaactca cgttaaggga 3480  
 ttttggctat gagattatca aaaaggatct tcacctagat ccttttaaat taaaaatgaa 3540  
 gttttaaatc aatctaaagt atatatgagt aaacttggtc tgacagttac caatgcttaa 3600  
 tcagttaggc acctatctca gogatctgtc tatttcgttc atccatagtt gcctgactcc 3660  
 ccgtcgtgta gataactacg atacgggagg gcttaccatc tggccccagt gctgcaatga 3720  
 taccgcgaga cccacgtca cgggtccag atttatcagc aataaaccag ccagccggaa 3780  
 gggccgagcg cagaagtggc cctgcaactt tatccgcctc catccagctt attaatgtt 3840  
 gccgggaagc tagagtaagt agttcgccag ttaatagttt gcgcaacgtt gttgccattg 3900  
 ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc ttcatcagc tccggtccc 3960  
 aacgatcaag gcgagttaca tgatcccca tgttgtgcaa aaaagcggtt agctccttcg 4020  
 gtccctccga cgttgtcaga agtaagttgg ccgcagtgtt atcaactcatg gttatggcag 4080  
 cactgcataa ttctcttact gtcatgcat ccgtaagatg cttttctgtg actggtgagt 4140  
 actcaaccaa gtcattctga gaatagtgtg tcggcgagcc gagttgctct tgcccggcgt 4200  
 caatacggga taataccgcg ccacatagca gaactttaa agtgctcatc attggaaaa 4260  
 gttcttcggg gcgaaaactc tcaaggatct taccgctgtt gagatccagt tcgatgtaac 4320

# EP 1 205 551 A1

ccactcgtgc acccaactga tcttcagcat cttttacttt caccagcggt tctgggtgag 4380  
 caaaaaacagg aaggcaaaat gccgcaaaaa aggggaataag ggcgacacgg aaatgttgaa 4440  
 5 tactcatact cttccttttt caatattatt gaagcattta tcagggttat tgtctcatga 4500  
 gcggatacat atttgaatgt atttagaaaa ataaacaaat aggggttccg cgcacatttc 4560  
 cccgaaaagt gccacctgac ggcacctgta gggcgccatt aagcgcgggc ggtgtggtgg 4620  
 ttacgcgcag cgtgacctgt acacttgcca ggcacctage gccgctcct ttcgctttct 4680  
 tcccttcctt tctcgccacg ttgcgggct tccccgta agctctaaat cgggggctcc 4740  
 10 ctttaggggt ccgatttagt gctttacggc acctcgacct caaaaaactt gattaggggtg 4800  
 atggttcacg tagtgggcca tcgacctgat agacgggttt tcgacctttg acgttgagg 4860  
 ccacgttctt taatagtggg ctcttggtcc aaactggaac aacactcaac cctatctcgg 4920  
 tctattcttt tgatttataa gggattttgc cgatttcggc ctattgggta aaaaatgagc 4980  
 15 tgatttaaca aaaatttaac gcgaatttta acaaaatatt aacgtttaca atttccatt 5040  
 cgcattccag gctgcgcaac tgttggaag ggcgatcggg gcgggctct tcgctattac 5100  
 gccagcccaa gctacctga taagtaagta atattaaggt acgggaggta cttggagcgg 5160  
 ccgcaataaa atatctttat ttccattaca tctgtgtgtt ggttttttgt gtgaatcgat 5220  
 20 agtactaaca tacgctctcc atcaaaacaa aacgaaacaa aacaaaactag caaaataggc 5280  
 tgtccccagt gcaagtgcag gtgccagaac atttctctat cgata 5325

<210> 51

25 <211> 5108

<212> DNA

<213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence:

pGHRH1-29WTCMV construct

<400> 51

35 gctgtgcctt ctagtgtcca gccatctgtt gtttgcacct ccccggtgcc ttcttgacc 60  
 ctggaagggt ccactccac tgtcctttcc taataaaatg aggaaattgc atcgattgt 120  
 ctgagtaggt gtcattctat tctgggggtt ggggtggggc aggacagcaa gggggaggat 180  
 tgggaagaca atagcaggca tgcgtgggat gcggtgggct ctatgggtac ccagggtgctg 240  
 40 aagaattgac ccggttcctc ctggggccaga aagaagcagg cacatccctt tctctgtgac 300  
 acacctgtc cagccctctg gttcttagtt ccagcccccac tcataggaca ctcatagctc 360  
 aggagggctc cgccttcaat cccacccgct aaagtacttg gagcgtctc tccctccctc 420  
 atcagccac caaaccaaac ctagcctcca agagtggga gaaattaaag caagatagc 480  
 45 tattaagtgc agaggagag aaaatgcctc caacatgtga ggaagtaatg agagaaatca 540  
 tagaatttct tccgcttctt cgtcactga ctgctgcgc tcggtcgttc ggtgcggcg 600  
 agcggtatca gctcaactca aggcggtaat acggttatcc acagaatcag gggataacgc 660  
 aggaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggcgcgctt 720  
 gctggcggtt ttccataggc tcggccccc tgacgagcat cacaaaaatc gacgctcaag 780  
 50 tcagagggtg cgaacccga caggactata aagataccag gcgtttcccc ctggaagctc 840  
 cctcgtgcgc tctcctgttc cgacctgcc gcttacggg tacctgtccg cctttctccc 900  
 ttccgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cgggtgtaggt 960  
 cgttcgctcc aagctgggt gtgtgcacga acccccggt cagcccgacc gctgcgcctt 1020  
 55 atccggtaac tatcgtcttg agtccaacc ggtaagacac gacttatcgc cactggcagc 1080  
 agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 1140

EP 1 205 551 A1

gtggtggcct aactacggct acactagaag aacagtatct ggtatctgcg ctctgctgaa 1200  
 gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaaaaaa ccaccgctgg 1260  
 5 tagcgggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 1320  
 agatcctttg atcttttcta cggggtctga cgctcagtgg aacgaaaact cagcttaagg 1380  
 gatttttggtc atgagattat caaaaaggat ctccacctag atccttttaa attaaaaatg 1440  
 aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgctt 1500  
 10 aatcagtgag gcacctatct cagcgatctg tctatttctg tcatccatag ttgcctgact 1560  
 cggggggggg gggcgctgag gtctgcctcg tgaagaagggt gttgctgact cataccaggc 1620  
 ctgaatcgcc ccacatcca gccagaaagt gagggagcca cggttgatga gagctttggt 1680  
 gtaggtggac cagttggtga ttttgaactt ttgctttgcc acggaacggt ctgcgttgct 1740  
 gggaagatgc gtgatctgat ccttcaactc agcaaaaagt cgatttattc aacaaagccg 1800  
 15 ccgtcccgtc aagtcagcgt aatgctctgc cagtgttaca accaattaac caattctgat 1860  
 tagaaaaact catcgagcat caaatgaaac tgcaatttat tcatatcagg attatcaata 1920  
 ccatattttt gaaaaagccg tttctgtaat gaaggagaaa actcaccgag gcagttccat 1980  
 aggatggcaa gatcctggta tcggtctgcg attccgactc gtcgaacatc aatacaacct 2040  
 20 attaatctcc cctcgtcaaa aataagggtta tcaagtgaga aatcaccatg agtgacgact 2100  
 gaatccggtg agaattggcaa aagcttatgc atttctttcc agacttgctc aacaggccag 2160  
 ccattacgct cgtcatcaaa atcactcgca tcaaccaaac cgttattcat tcgtgattgc 2220  
 gcctgagcga gacgaaatac gcgatcgctg ttaaaaggac aattacaaac aggaatcgaa 2280  
 tgcaaccggc gcaggaaacac tgccagcgca tcaacaatat ttccacctga atcaggatat 2340  
 25 tcttctaata cctggaatgc tgttttcccg gggatcgag tggtgagtaa ccatgcatca 2400  
 tcaggagtac ggataaaatg cttgatggtc ggaagaggca taaattccgt cagccagttt 2460  
 agtctgacca tctcatctgt aacatcattg gcaacgctac ctttgccatg ttccagaaac 2520  
 aactctggcg catcggtctt cccatacaat cgatagattg tcgcaactga ttgcccagca 2580  
 30 ttatcgcgag cccatttata cccatataaa tcagcatcca tgttggattt taatcgcgcg 2640  
 ctcgagcaag acgtttcccg ttgaatatgg ctcataaac ccttctgatt actgtttatg 2700  
 taagcagaca gttttattgt tcatgatgat atatttttat ctctgtgcaat gtaacatcag 2760  
 agattttgag acacaaagtg gctttccccc cccccccatt attgaagcat ttatcagggt 2820  
 tattgtctca tgagcggata catatttgaa tgtatttaga aaaataaaca aataggggtt 2880  
 35 ccgcgcacat ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 2940  
 ttaacctata aaaaaggcgt tatcacgagg cctttctgct ctgcgcgctt tcgggtgatga 3000  
 cgggtgaaaac ctctgacaca tgcagctccc ggagacggct acagcttgct tgtaagcgga 3060  
 tgccgggagc agacaagccc gtcaggggcg gtcagcgggt gttggcgggt gtcggggctg 3120  
 40 gcttaactat gcggcatcag agcagattgt actgagagt caccatattg ggtgtgaaat 3180  
 accgcacaga tgcgtaagg gaaaataccg catcagattg gctattggcc attgcatacg 3240  
 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgcatgt 3300  
 tgacattgat tattgactag ttattaatag taatcaatta cggggtcatt agttcatagc 3360  
 45 ccatatatgg agttccgctg tacataactt acggtaaatg gccgcctgg ctgaccgccc 3420  
 aacgaccccc gccattgac gtcaataatg acgtatgttc ccatagtaac gccaataggg 3480  
 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt ggcagtacat 3540  
 caagtgtatc atatgccaag tacgcccctt attgacgtca atgacggtaa atggcccgcc 3600  
 tggcattatg ccagttacat gaccttatgg gactttccta cttggcagta catctacgta 3660  
 50 ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag 3720  
 cggtttgact cagggggatt tccaagtctc caccctattg acgtcaatgg gagtttgttt 3780  
 tggcaccaaa atcaacggga ctttccaaaa tgcgtgaaca actccgcccc attgacgcaa 3840  
 atgggcggta ggcgtgtacg gtgggaggtc tatataagca gagctcgttt agtgaaccgt 3900  
 55 cagatcgctt ggagacgcca tccacgctgt tttgacctc atagaagaca ccgggacgga 3960  
 tccagcctcc gcggccggga acggtgcatt ggaacggga ttccccgtgc caagagtgc 4020



# EP 1 205 551 A1

```

5   gtaagtaccg cctatagact ctataggcac acccctttgg ctcttatgca tgctatactg 4080
    tttttggcct ggggcctata ccccccgct tecttatgct ataggtgatg gtatagctta 4140
    gcctataggt gtgggttatt gaccattatt gaccactccc ctattggtga cgatactttc 4200
    cactactaat ccataacatg gctctttgcc acaactatct ctattggcta tatgccaaata 4260
    ctctgtcctt cagagactga caggactct gtatttttac aggatggggt cccattttatt 4320
    atttacaat tcacatatac aacaacgcg tccccgtgc cgcagtttt tattaacat 4380
    agcgtgggat ctccacgcga atctcggtta cgtgttcgg acatgggctc ttctccggtta 4440
10  gcggcggagc ttccacatcc gagccctggt cccatgcctc cagcggctca tggtcgctcg 4500
    gcagctcctt gtcctaaca gtggaggcca gacttaggca cagcacaatg cccaccacca 4560
    ccaglglgcc gcacaaggcc gtggcggtag ggtatgtgtc tgaaaatgag cgtggagatt 4620
    gggctgcac ggctgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca 4680
15  gctgagttgt tgtattctga taagagtcag aggttaactcc cgttgcggtg ctgttaacgg 4740
    tggagggcag ttagtctga gcagtactcg ttgctgccgc gcgcgccacc agacataata 4800
    gctgacagac taacagactg ttccctttcca tgggtctttt ctgcagtcac cgtcgtcgac 4860
    acgtgtgatc agatatcgcg gccgctctag accaggcgcc tggatccgcc accatgccac 4920
20  tctgggtggt ctctcttggt atcctcacc tcagcaacag ctcccactgc tccccacctc 4980
    cccctttgac cctcaggatg cggcggtatg cagatgccat cttcaccac agctaccgga 5040
    aggtgctggg ccagctgtcc gcccgcaagc tgetccagga catcatgagc aggtagagat 5100
    ccagatct                                     5108

```

25

<210> 52

<211> 5108

<212> DNA

30

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

35

pGHRH1-29YWTCMV construct

<400> 52

40

```

    gctgtgcctt ctagttagca gccatctgtt gtttgccct ccccggtgc ttccctgacc 60
    ctggaagggt ccactccac tgtcctttcc taataaaatg aggaaattgc atcgcatgt 120
    ctgagtaggt gtcattctat tctggggggt ggggtgggc aggacagcaa gggggaggat 180
    tgggaagaca atagcaggca tgcctgggat gcgggtggct ctatgggtac ccaggtgctg 240
    aagaattgac ccggttcctc ctgggccaga aagaagcagg cacatccct tctctgtgac 300
    acaccctgtc cagccccctg gttccttagt ccagccccac tcataggaca ctcatagctc 360
45  aggagggctc gccttcaat cccacccgct aaagtaettg gagcggtctc tccctccctc 420
    atcagcccc caaaccaaac ctagcctcca agagtgggaa gaaattaaag caagataggc 480
    tattaagtgc agagggagag aaaatgcctc caacatgtga ggaagtaatg agagaaatca 540
    tagaaattct tccgcttcc cgtcactga ctgcgtgcgc tgggtcgctc ggctgcggcg 600
50  agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc 660
    aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggcgcggt 720
    gctggcgttt ttccataggc tccgcccccc tgacgagcat caaaaaaatc gacgtcaag 780
    tcagaggtgg cgaacccga caggactata aagataccag gcgtttcccc ctggaagctc 840
    cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cttttctccc 900
55  ttccgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cgggtgtaggt 960
    cgttcgctcc aagctgggct gtgtgcacga acccccggt cagcccgacc gctgcgcctt 1020

```

EP 1 205 551 A1

atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc 1080  
 agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 1140  
 5 gtgggtggcct aactacgget acactagaag aacagtatct ggtatctgcg ctctgctgaa 1200  
 gccagttacc ttccgaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg 1260  
 tagcgggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 1320  
 agatcctttg atctttttcta cggggtctga cgtcagtggt aacgaaaact cactgtaagg 1380  
 gatttttggtc atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg 1440  
 10 aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgctt 1500  
 aatcagtgag gcacctatct cagcgatctg tctatttctg tcatccatag ttgcctgact 1560  
 cggggggggg gggcgctgag gtctgcctcg tgaagaaggt gttgctgact cataccaggc 1620  
 ctgaatcgcc ccatcatcca gccagaaagt gaggagcca cggttgatga gagctttggt 1680  
 15 gtaggtggac cagttggtga ttttgaactt ttgctttgcc acggaacggt ctgcgttgctc 1740  
 gggaagatgc gtgatctgat ccttcaactc agcaaaaagt cgatttatto aacaaagccg 1800  
 ccgtcccgtc aagtcagcgt aatgctctgc cagtgttaca accaatatac caattctgat 1860  
 tagaaaaact catcgagcat caaatgaaac tgcaatttat tcatatcagg attatcaata 1920  
 20 ccatattttt gaaaaagccg tttctgtaat gaaggagaaa actcaccgag gcagttccat 1980  
 aggatggcaa gatcctggtg tgggtctgcg attccgaact gtccaacatc aatacaacct 2040  
 attaatctcc cctcgctcaa aataagggtt tcaagtgaga aatcaccatg agtgacgaact 2100  
 gaatccgggtg agaatggcaa aagcttatgc atttctttcc agacttgctc aacaggccag 2160  
 ccattacgct cgtcatcaaa atcactcgca tcaacaaaac cgttatccat tctgtattgc 2220  
 25 gcctgagcga gacgaaatac gcgatcgctg ttaaaaaggac aattacaaac aggaatcgaa 2280  
 tgcaaccggc gcaggaacac tgccagcgca tcaacaatat tttcacctga atcaggatat 2340  
 tcttctaata cctggaatgc tgttttcccg gggatcgcag tggtagtaaa ccatgcatca 2400  
 tcaggagtac ggataaaatg cttgatggtc ggaagaggca taaattccgt cagccagttt 2460  
 30 agtctgacca tctcatctgt aacatcattg gcaacgctac ctttgccatg ttccagaaac 2520  
 aactctggcg catcgggctt cccatacaat cgatagattg tcgcacctga ttgcccagca 2580  
 ttatcgcgag cccatttata cccatataaa tcagcatcca tgttggaatt taatcgcggc 2640  
 ctcgagcaag acgtttcccg ttgaatatgg ctcataacac cccttgattt actgtttatg 2700  
 taagcagaca gttttattgt tcatgatgat atatttttat cttgtgcaat gtaacatcag 2760  
 35 agattttgag acacaacgtg gctttccccc cccccccatt attgaagcat ttatcagggt 2820  
 tattgtctca tgagcggata catatttgaa tgtatttaga aaaataaaca aataggggtt 2880  
 ccgcgcacat ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 2940  
 ttaacctata aaaataagcg tatcacgagg ccttttcgtc ctgcgcgctt tccgtgatga 3000  
 40 cggtgaaaac ctctgacaca tgcagctccc ggagacggtc acagcttgctc tgtaagcgga 3060  
 tgccgggagc agacaagccc gtcagggcgc gtcagcgggt gttggcgggt gtccgggctg 3120  
 gcttaactat gcggcatcag agcagattgt actgagagtg caccatatgc ggtgtgaaat 3180  
 accgcacaga tcggtgaagga gaaaataacc catcagattg gctatttgcc attgcatacg 3240  
 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgccatgt 3300  
 45 tgacattgat tattgactag ttattaatag taatcaatta cggggtcatt agttcatagc 3360  
 ccatatatgg agttccgcgt tacataaact acggtaaatg gccgcctggt ctgaccgccc 3420  
 aacgaccccc gccattgac gtcaataatg acgtatgttc ccatagtaac gccaataggg 3480  
 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgccactt ggcagtacat 3540  
 50 caagtgtatc atatgccaa gtaacccctt attgacgtca atgacggtaa atggcccgc 3600  
 tggcattatg ccagtcacat gaccttatgg gactttccta cttggcagta catctacgta 3660  
 ttagtcatcg ctattacat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag 3720  
 cggtttgact caccgggatt tccaagtctc caccocattg acgtcaatgg gagtttgttt 3780  
 55 tggcaccaaa atcaacggga ctctccaaaa tgcgtgaaca actccgccc attgacgcaa 3840  
 atgggcggta ggcgtgtacg gtgggaggtc tatataagca gagctcgttt agtgaaccgt 3900

# EP 1 205 551 A1

5 cagatcgctt ggagacgcca tccacgtgtt ttgacctcc atagaagaca ccgggaccga 3960  
 tccagcctcc gcggccggga acggtgcatt ggaacgcgga ttccccgtgc caagagtgc 4020  
 gtaagtaccg cctatagact ctataggcac acccctttgg ctcttatgca tgctatactg 4080  
 tttttggctt ggggcctata cacccccgtt tccttatgct ataggtgatg gtatagctta 4140  
 gcctataggt gtgggttatt gaccattatt gaccactccc ctattgggtga cgatactttc 4200  
 cattactaat ccataacatg gctctttgcc acaactatct ctattggcta tatgccaata 4260  
 10 ctctgtcctt cagagactga cagggactct gtatttttac aggatggggt cccattttatt 4320  
 atttacaat tcacatatac aacaacgcg tccccgtgc ccgcagtttt tattaacat 4380  
 agcgtgggat ctccacgcga atctcgggtg cgtgttcggg acatgggctc ttctccggta 4440  
 gcggcgggagc ttccacatcc gagccctggg cccatgcctc cagcggctca tggctgcctg 4500  
 gcagctcctt gctcctaaca gtggaggcca gacttaggca cagcacaatg cccaccacca 4560  
 15 ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc tgaaaatgag cgtggagatt 4620  
 gggctcgcac ggctgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca 4680  
 gctgagttgt tgtattctga taagagtcag aggttaactcc cgttgcgggtg ctgttaacgg 4740  
 tggaggggcag tgtagtctga gcagtactcg ttgctgccgc gcgcgccacc agacataata 4800  
 20 gctgacagac taacagactg ttcttttcca tgggtctttt ctgcagtcac cgtcgtcgac 4860  
 acgtgtgatc agatatcgcg gccgctctag accaggcgcc tggatccgcc accatgccac 4920  
 tctgggtgtt ctcttttggt atctcacc ctagcaacag ctcccactgc tccccacctc 4980  
 cccctttgac cctcaggatg cggcggtatg cagatgccat ctccaacca acgtaccgga 5040  
 aggtgctggg ccagctgtcc gcccgcaagc tctccagga catcatgagc aggtagagat 5100  
 25 ccagatct 5108

30 <210> 53  
 <211> 3954  
 <212> DNA  
 <213> Artificial Sequence

35 <220>  
 <223> Description of Artificial Sequence:  
 pGHRH1-29YWTSK685 construct

40 <400> 53  
 ggtaccatcg ctggggagct gggggagggg tgccttctt gccctacca ggaactccggg 60  
 tgcgaccgct cctctatctc tccagccac caccactcca ccacttgac acgtctccct 120  
 cctccctgga gtgcctctag agggtttggg ggtctgagta aagaaccga agtagggata 180  
 cagtgtggcg gcaccttcca gagggcccg gcgcagggtg gaccggggcg gggcgggccg 240  
 45 cggacagggt cagccccagg cgcaggcgca ctccgcctc ccggcgagc cgggtgaacct 300  
 cgccccacc cagccctcc ggggggcagc tgggcgggt cgggaggggc ccaccagccc 360  
 gggagacact ccatatacgg ccaggcccg tttacctggg ctccggccag gccgctcctt 420  
 ctttggtcag cacaggggac ccgggcgggg gcccaggccg ctaaccggcc gggggagggg 480  
 gctccagtgc ccaacacca aatatggctc gagaagggga gcgacattcc agtgaggcgg 540  
 50 ctccggggga gaaccgcgg gctatataaa acctgagcgt ggggaccagc ggccaccgca 600  
 gcggacagcg ccgagagaag cctcgttcc ctcccgggc gaccagggcc ccagccggag 660  
 agcagcagg gttagccacca agcttgccac catgccactc tgggtgttct tctttgtgat 720  
 cctcaccctc agcaacagct cccactgctc cccacctccc cctttgacct tcaggatgcg 780  
 55 gcggattat gcagatgcca tcttcacaa cagctaccgg aaggtgctgg gccagctgtc 840  
 cgcccgcaag ctctccagg acatcatgag caggtagtct agagtcgggg cggccggccg 900

EP 1 205 551 A1

5      ctctcgagcag acatgataag atacattgat gagtttggac aaaccacaac tagaatgcag 960  
 tgaaaaaaat gctttatttg tgaaatttgt gatgctattg ctttatttgt aaccattata 1020  
 agctgcaata aacaagttta caacaacaat tgcattcatt ttatgtttca gggttcagggg 1080  
 gaggtgtggg aggtttttta aagcaagtaa aacctctaca aatgtggtaa aatcgataag 1140  
 gatccgtcga ccgatgccct tgagagcctt caaccagtc agctccttcc ggtgggcgcg 1200  
 gggcatgact atcgtcgccg cacttatgac tgtcttcttt atcatgcaac tcgtaggaca 1260  
 10      ggtgcccga gcgctcttcc gcttctctgc tcaatgactc gctgcgctcg gtcgttcggc 1320  
 tgcggcgagc ggtatcagct cactcaaagg cgtaataacg gttatccaca gaatcagggg 1380  
 ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa ggccagggaac cgtaaaaagg 1440  
 ccgctgttgc ggctttttc cataggtctc gccccctga cgagcatcac aaaaatcgac 1500  
 15      gctcaagtca gaggtggcga aaccgcacag gactataaag ataccaggcg tttccccctg 1560  
 gaagctccct cgtgcgctct cctgttccga cctgcgcgt taaccgatac ctgtccgcct 1620  
 ttctcccttc gggaagcgtg gcgctttctc aatgctcac ctgtaggat ctcaagtccg 1680  
 tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag ccgacccgt 1740  
 gcgcttctc cggttaactat cgtcttgagt ccaaccggg aagacacgac ttatcgccac 1800  
 20      tggcagcagc cactggtaac aggattagca gagcgaggta tgtaggcggt gctacagagt 1860  
 tcttgaagtg gtggcctaac tacggctaca ctagaaggac agtatttgg atctgcgctc 1920  
 tgcgtgaagc agttacctc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca 1980  
 ccgctggtag cgggtgtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat 2040  
 25      ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc tcagtggaa gaaaactcac 2100  
 gtttaagggt tttggtcatg agattatcaa aaaggatctt cacctagatc cttttaaatt 2160  
 aaaaatgaag ttttaaatca atctaaagta tatatgagta aacttggct gacagttacc 2220  
 aatgcttaat cagtgaaggc cctatctcag cgatctgtct atttcgttca tccatagttg 2280  
 cctgactccc cgtcgtgtag ataactacga tacgggaggg cttaccatct ggccccagt 2340  
 30      ctgcaatgat accgcgagac ccacgctcac cggctccaga tttatcagca ataaccagc 2400  
 cagccggaag ggccgagcgc agaagtggc ctgcaacttt atccgcctcc atccagtcta 2460  
 ttaattgttg ccgggaagct agagtaagta gttcgccagt taatagtttg cgcaacggtg 2520  
 ttgccattgc tacaggcatc gtggtgtcac gctcgtcgtt tggataggct tcattcagct 2580  
 35      ccggttccca acgatcaagg cgagttacat gatccccat gttgtgcaaa aaagcgggta 2640  
 gctccttcgg tctccgacg gttgtcagaa gtaagtggc cgcagtgtta tcaatcatgg 2700  
 ttatggcagc actgcataat tctcttactg tcatgcoac cgtaagatgc ttttctgtga 2760  
 ctggtgagta ctcaaccaag tcattctgag aatagtgtat gcggcgaccg agttgctctt 2820  
 gcccggcgtc aatacgggat aataccgcgc cacatagcag aactttaaaa gtgctcatca 2880  
 40      ttggaaaaacg ttcttcgggg cgaaaactct caaggatctt accgctgttg agatccagtt 2940  
 cgatgtaacc cactcgtgca cccaactgat cttcagcatc ttttactttc accagcgttt 3000  
 ctgggtgagc aaaaacagga aggcataatg ccgcaaaaaa ggaataaagg gcgacacgga 3060  
 aatgttgaat actcatactc ttctcttttc aatattattg aagcatttat cagggttatt 3120  
 45      gtctcatgag cggatacata tttgaatgta tttagaaaaa taaacaaata ggggttccgc 3180  
 gcacatttcc ccgaaaagtg caactgacg gcgctgtag cggcgcatca agcgggcgg 3240  
 gtgtggtggt tacgcgcagc gtgacgcgta caattgccag cgccctagcg ccgctcctt 3300  
 tcgcttctct ccttctctt ctgcgcacgt tcgcggctt tccccgtcaa gctctaaatc 3360  
 gggggtctcc tttagggttc cgatttagtg ctttacggca cctcgacccc aaaaaacttg 3420  
 50      attagggtga tggttcacgt agtgggccat cgccctgata gacggttttt cgcccttga 3480  
 cgttggagtc cagttctttt aatagtggac tcttgttcca aactggaaca acaactcaac 3540  
 ctatctcggg ctattctttt gatttataag ggattttgac gatttcggcc tattggttaa 3600  
 aaaatgagct gatttaacaa aaatttaacg cgaattttta caaaatatta acgtttacaa 3660  
 55      tttcccatcc gccattcagg ctgcgcacgt gttgggaagg gcgatcgggt cgggcctctt 3720  
 cgctattacg ccagcccaag ctaccatgat aagtaagtaa tattaaggta cgggaggtac 3780

# EP 1 205 551 A1

5      ttggagcggc cgcaataaaa tatctttatt ttcattacat ctgtgtgttg gttttttgtg 3840  
tgaatcgata gtactaacat acgctctcca tcaaaacaaa acgaaacaaa acaaactagc 3900  
aaaataggct gtccccagtg caagtgcagg tgccagaaca tttctctatc gata            3954

<210> 54

<211> 5163

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

pGHRH1-29YWTSK2014 construct

<400> 54

20      ggtaccgcta taggagagaa aagagctgca ctgagcacc ccttcccct ttaaagtca 60  
acagattagg agtcagtga tgacagcaca cctcttgcta ccttagagac caaaatttaa 120  
gtactcccc ttaagctata gctagagtgc acctgccagt gtcttttagtc cccactgatg 180  
gaacaggacc caaggtattg aagatggaac atagtatttc attcaccctc taatttataa 240  
agctggatat gctgtacagc agaaattgac ggaacaatgt aaatcaacta taacagaaga 300  
25      aataaaaacc tggggggaaa gaagctgact atgaaacccc aggagctttc tacatgggcc 360  
tggaactcacc aaactcttta ttttgtaatg gacttctgac attttttagga agggctgtcc 420  
tgatgtgggc tatagaagag ggtttcacat gcttcttcaa gaggaccac actgtcccag 480  
ttgctgagtc ccaccaccag atgctagtgg cagctatttg gggaacactt aggcactaca 540  
30      aaaaaatgag tgattccatt ctggctcaca ccataccct gatgtacccc ttaaagcatg 600  
tcaactgagtt catcacagaa aattgtttcc cctgtgcctt ccacaacaag gtttagagctg 660  
tcttgggggc caggggaagg gggcagggag tgagaagcac caactggata acctcctctg 720  
acccccactc caccctacca taagtagatc caaatccttc tagaaaatta ggaaggcata 780  
tccccatata tcagcgatat aaatagaact gcttcagcgc totggtagac ggtgactctc 840  
35      caaggtggac tgggaggcag cctggccttg gctgggcac gtcctctaaa tagaaagatg 900  
aacttggtta gcctttccag aaggaaaact gctgcccagc ctacagtga acgtccttgt 960  
cttccatctg gaggaagcac ggtgacata tcacttagta agggcacctc tctgtttcca 1020  
cctccaggtc gaggggtgtg accttactt ctcagcctca agggaggagc actcaacccc 1080  
40      ccaaaaagac atgagggcgc tcagctcggc ccaccgcacc ccggaccgga gccgtcacc 1140  
ccgaaaattc actcccttca caagccccc agcgcgttct ctggtgcgga ctgctccggg 1200  
gccctggctt tgtgccagc gttgtcagag ccaccgcct gagcctgtcc ccgggagccc 1260  
cgcgcctcct ccaccgctc cgtctctcgc ccccgcgccc agttgtctgc ccgagacag 1320  
45      ctgcgcgccc tcccgtgcc ggtggccctc tccggtggg gtggggaccg acagggtcag 1380  
ccctccggat ccggggcgct ccgggtagcg gggagaagt atcgctggg agctggggga 1440  
ggggtcgcct tctgccccta ccaggactc cgggtgcgac cgtcccteta tctctccagc 1500  
ccgggcgcag ggtagaccg ggcggggcg cccgcggaca ggtgcagccc caggcgcagg 1560  
cgactcgcg cctcccggcg caggcgggtga acctcgcccc accccagccc ctccgggggg 1620  
50      cagctggggc gggtcgggag gggcccacca gccggggaga cactccatat acggccaggc 1680  
ccgctttacc tgggtccgg ccaggccgct ccttcttttg tcagcacagg ggaccgggg 1740  
gggggcccag gccgctaacc cgcgggggga gggggctcca gtgcccaca cccaaatatg 1800  
gtcgcagaag gggagcgaca ttccagttag gcggtcctgg gggagaaccc gcgggctata 1860  
55      taaaacctga gcgtggggac cagcggccaa gcttgcaccc atgccactct ggggtgttctt 1920  
ctttgtgac ctcacctca gcaacagctc ccactgctcc ccacctcccc ctttgacctt 1980

EP 1 205 551 A1

caggatgcgg cggattattg cagatgccat cttaccaaac agctaccgga aggtgctggg 2040  
 ccagctgtcc gcccgcaagc tctccagga catcatgagc aggtagtcta gaggcgggc 2100  
 5 ggcggcgcgc ttcgagcaga catgataaga tacattgatg agtttgaca aaccacaact 2160  
 agaatgcagt gaaaaaaatg ctttatttgt gaaatttgtg atgctattgc tttatttcta 2220  
 accattataa gctgcaataa acaagttaac aacaacaatt gcattcattt tatgtttcag 2280  
 gttcaggggg aggtgtggga ggttttttaa agcaagtaaa acctctacaa atgtggtaaa 2340  
 10 atcgataagg atccgtcgac cgatgccctt gagagccttc aaccagtcga gctccttcgc 2400  
 gtgggcgcgc ggcattgact tgcgtgcgcg acttatgact gtcttcttta tcatgcaact 2460  
 cgtaggacag gtgcccgcag cgtctcttcg ctctctcgt cactgactcg ctgcgctcgc 2520  
 tcttccggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag 2580  
 aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccagggaacc 2640  
 15 gtaaaaaggc cgcgttgctg gcgtttttcc ataggctcgc cccctctgac gagcatcaca 2700  
 aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt 2760  
 tccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc 2820  
 tgcgcgctt tctccctcg ggaagcgtgg cgtttctca atgctcagc tgtaggatc 2880  
 20 tcatgtcgtt gtaggtcgtt cgtcccaagc tgggtgtgt gcacgaacc cccgttcagc 2940  
 ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caaccggta agacacgact 3000  
 tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggatg ttaggcggtg 3060  
 ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttgga 3120  
 25 tctgcgctct gctgaagcca gttaccctcg gaaaaagagt tggtagctct tgatccggca 3180  
 aacaaaccac cgtcgttagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa 3240  
 aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgaogct cagtggaaacg 3300  
 aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc 3360  
 ttttaatta aaaaatgaagt ttaaatcaa tctaaagtat atatgagtaa acttggtctg 3420  
 30 acagttacca atgcttaato agtgaggcac ctatctcagc gatctgtcta ttcgttcat 3480  
 ccatagttgc ctgactcccc gtctgttaga taactacgat acgggagggc ttaccatctg 3540  
 gccccagtcg tgcaatgata ccgcgagacc cagctcacc ggctccagat ttalcagcaa 3600  
 taaaccagcc agccggaagg gccgagcgca gaagtggctc tgcaacttta tccgcctcca 3660  
 35 tccagcttat taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc 3720  
 gcaacgttgt tgcattgct acaggcatcg tgggtgcacg ctctcgttct ggtatggctt 3780  
 cattcagctc cgttcccaa cgatcaaggc gagttacatg atccccatg ttgtgcaaaa 3840  
 aagcgttag ctcttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgtat 3900  
 cactcatggt tatggcagca ctgcataatt ctcttactgt catgcatcc gtaagatgct 3960  
 40 tttctgtgac tggtagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga 4020  
 gttgctcttg cccggcgtca atacgggata ataccgcgc acatagcaga actttaaaag 4080  
 tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga 4140  
 gatccagttc gatgtaacc accgtgtcac ccaactgac ttcagcatct tttactttca 4200  
 45 ccagcgttcc tgggtgagca aaaacaggaa ggcaaatgc cgcaaaaaag ggaataaggg 4260  
 cgacacggaa atgttgaata ctcatctct tctttttca atattattga agcatttctc 4320  
 aggtttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag 4380  
 ggttcccgcg cacatttccc cgaagggtgc cactgacgc gccctgtagc ggcgcattaa 4440  
 50 gcgcggcggg tgtggtggtt acgcgcagcg tgaccgctac acttgccagc gccctagcgc 4500  
 ccgtcctttt cgtttcttcc ccttcttctc tgcgaagctt cgcgggcttt cccgtcaag 4560  
 ctctaaatcg ggggtctcct ttaggttcc gatttagtgc tttacggcac ctgacccca 4620  
 aaaaacttga ttaggtgat ggttcacgta gtgggccatc gccctgatag acggttttcc 4680  
 gccctttgac gttggagtcc acgttcttta atagtggact ctgtttccaa actggaacaa 4740  
 55 cactcaacc tatctcggtc tattctttt atttataagg gattttgcgc atttcggcct 4800  
 attggttaaa aatgagctg atttaacaaa aatttaacgc gaattttaac aaaaatttaa 4860

# EP 1 205 551 A1

cgttttacaat ttcccatcgc ccattcaggc tgcgcaactg ttgggaaggg cgatcgggtgc 4920  
 gggcctcttcc gctattacgc cagocccaagc taccatgata agtaagtaat attaaggtac 4980  
 5 gggaggtact tggagcggcc gcaataaaat atctttatctt tcattacatc tgtgtgttgg 5040  
 ttttttgtgt gaatcgatag tactaacata cgctctccat caaaacaaaa cgaaacaaaa 5100  
 caaactagca aaataggctg tcccagtgcc aagtgcagggt gccagaacat ttctctatcg 5160  
 ata 5163

10

<210> 55

<211> 5111

<212> DNA

15

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

20

pGHRH1-29Yala1522CMV construct

<400> 55

25

gctgtgcctt ctagttgccg gccatctggt gtttgcccct ccccggtgcc ttccttgacc 60  
 ctggaaggtg ccaactccac tgcctcttcc taataaaatg aggaaattgc atcgatttgt 120  
 ctgagtaggt gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat 180  
 tgggaagaca atagcaggca tgctggggat gcggtgggct ctatgggtac ccaggtgctg 240  
 aagaattgac cgggttcctc ctgggccaga aagaagcagg cacatccctt tctcgtgac 300  
 acacctgtgc cagccccctg gttcttagtt ccagccccac tcataggaca ctcatagctc 360  
 30 aggagggctc cgcccttcaat cccaccgct aaagtacttg gagcggtctc tccctccctc 420  
 atcagccccc caaaccaaac ctagcctcca agagtgggaa gaaattaaag caagataggc 480  
 tattaagtgc agagggagag aaaatgcctc caacatgtga ggaagtaatg agagaaatca 540  
 tagaatttct tccgcttctc cgtcactga ctgctgctgc tgggtcgttc ggctgcggcg 600  
 agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc 660  
 35 aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggcgcgctt 720  
 gctggcgctt ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag 780  
 tcagaggtgg cgaaaccgca caggactata aagataccag gcgtttcccc ctggaagctc 840  
 cctcgtgcgc tctcctgttc cgaccctgcc gcttaaccgga tacctgtccg cctttctccc 900  
 40 ttccgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cgggtgtaggt 960  
 cgttcgcctc aagctgggct gtgtgcacga acccccgtt cagcccgacc gctgcgcctt 1020  
 atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc 1080  
 agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 1140  
 45 gtgggtggcct aactacggct aactagaag aacagtattt ggtatctgag ctctgctgaa 1200  
 gccagttacc ttccgaaaaa gaggtagtag ctcttgatcc ggcaaaacaa ccaccgctgg 1260  
 tagcgggtgt tttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 1320  
 agatcctttg atcttttcta cggqgtctga cgtcagtggt aacgaaaact caggttaagg 1380  
 gatttttggtc atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg 1440  
 50 aagtttttaa tcaatctaaa gtatatatga gttaaacttg tctgacagtt accaatgctt 1500  
 aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag ttgcctgact 1560  
 cggggggggg gggcgctgag gtctgcctcg tgaagaagggt gttgctgact cataccaggc 1620  
 ctgaatcgcc ccatcatcca gccagaaagt gagggagcca cgggtgatga gagctttgtt 1680  
 55 gtaggtggac cagttggtga ttttgaaact ttgctttgcc acggaacggt ctgcgttgct 1740  
 gggaagatgc gtgatctgat cttcaactc agcaaaaagt cgatttatcc aacaaagccg 1800

EP 1 205 551 A1

cccgtcccgtc aagtcagcgt aatgctctgc cagtgttaca accaattaac caattctgat 1860  
 tagaaaaact catcgagcat caaatgaaac tgcaatttat tcatatcagg attatcaata 1920  
 5 ccatatTTTT gaaaaagccg tttctgtaat gaaggagaaa actcaccgag gcagttccat 1980  
 aggatggcaa gatcctggta tcggtctgcg attccgactc gtccaacatc aatacaacct 2040  
 attaatTTCC cctcgtcaaa aataaggTTa tcaagtgaga aatcaccatg agtgacgact 2100  
 gaatccggtg agaatggcaa aagcttatgc atttctttcc agacttgTtc aacaggccag 2160  
 ccattacgct cgtcatcaaa atcactcgca tcaaccaaac cgttattcat tcgtgattgc 2220  
 10 gcctgagcga gacgaaatac gcgatcgctg ttaaaaggac aattacaaac aggaatcgaa 2280  
 tgcaaccggc gcaggaacac tgccagcgca tcaacaatat tttcacctga atcaggatat 2340  
 tcttctaata cctggaatgc tgTTTTcccg gggatcgcg tggtgagtaa ccatgcatca 2400  
 tcaggagtag ggataaaatg cttgatggtc ggaagaggca taaattccgt cagccagttt 2460  
 15 agtctgacca tctcatctgt aacatcattg gcaacgctac ctttgccatg tttcagaaac 2520  
 aactctggcg catcgggctt cccatacaat cगतगattg tcgcacctga ttgcccga 2580  
 ttatcgcgag cccatttata cccatataaa tcagcatcca tgTTggaatt taatcgcgcc 2640  
 ctcgagcaag acgtttcccg ttgaatatgg ctcaatacac ccttTgtatt actgtttatg 2700  
 20 taagcagaca gttttattgt tcatgatgat atatttttat cttgtgcaat gtaacatcag 2760  
 agattttgag acacaacgtg gctttccccc cccccccatt attgaagcat ttatcagggt 2820  
 tattgtctca tgagcggata catatttgaa tgtattttaga aaaataaaca aataggggtt 2880  
 ccgcgcacat ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 2940  
 ttaacctata aaaataggcg tatacagagg cctttctgct ctcgcgcgtt tcggtgatga 3000  
 25 cggtgaaaac ctctgacaca tgcagctccc ggagacggtc acagcttgTc tgtaagcggg 3060  
 tgccgggagc agacaagccc gtcagggcgc gtcagcgggt gttggcgggt gtcggggctg 3120  
 gcttaactat gcggcatcag agcagattgt actgagagtg caccatatgc ggtgtgaaat 3180  
 accgcacaga tgcgtaagga gaaaataccg catcagattg gctattggcc attgcatacg 3240  
 30 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgccatgt 3300  
 tgacattgat tattgactag ttattaatag taatcaatta cggggTcatt agttcatagc 3360  
 ccatatatgg agttccgcgt tacataactt acggtaaatg gcccgcctgg ctgaccgccc 3420  
 aacgaccccc gccattgac gtcaataatg acgtatgttc ccatagtaac gccaataggg 3480  
 35 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgccactt ggcagtacat 3540  
 caagtgtatc atatgccaaag tacgccccct attgacgtca atgacggtaa atggcccgcc 3600  
 tggcattatg cccagtagat gacottatgg gactttccta cttggcagta catctacgta 3660  
 ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag 3720  
 cggtttgact caccgggatt tccaagtctc cccccattg acgtcaatgg gagtttgTtt 3780  
 40 tggcaccaaa atcaacggga ctttccaaaa tgtcgtaaca actccgcccc attgacgcaa 3840  
 atgggcggta ggcggtgtac gtgggaggtc tatataagca gagctcgTtt agtgaacctg 3900  
 cagatcgctt ggagacgcca tccacgctgt tttgacctc atagaagaca ccgggacoga 3960  
 tccagcctcc gggccgggga acggtgcatt ggaacgcgga ttccccgtgc caagagtgc 4020  
 45 gtaagtaccg cctatagact ctataggcac acccctttgg ctcttatgca tgctatactg 4080  
 tttttggctt ggggcctata ccccccgct tecttatget ataggtgatg gtatagctta 4140  
 gcctataggt gtgggttatt gaccattatt gaccactccc ctattggTga cgatactttc 4200  
 cattaactaat ccataacatg gctctttgcc acaactatct ctattggcta tatgccaaata 4260  
 50 ctctgtcctt cagagactga caccgactct gtatttttac aggatggggT cccatttatt 4320  
 atttacaat tccatatac aacaacgcg tccccgtgc ccgcagtttt tattaaacat 4380  
 agcgtgggat ctccacgca atctcgggta cgtgttcccg acatgggctc ttctccggta 4440  
 gggcgggagc ttccacatcc gagccctggT cccatgcctc cagcggtca tggtcgctcg 4500  
 gcagctcctt gctcctaaca gtggaggcca gacttaggca cagcacaatg cccaccacca 4560  
 55 ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc tgaaaatgag cgtggagatt 4620  
 gggctcgcac ggctgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca 4680



# EP 1 205 551 A1

5 gctgagttgt tgtattctga taagagtcag aggttaactcc cgttgcggtg ctgttaacgg 4740  
 tggaggggcag tgtagtctga gcagtactcg ttgctgccgc gcgcgccacc agacataata 4800  
 gctgacagac taacagactg ttccctttcca tgggtctttt ctgcagtcac cgtcgtcgac 4860  
 acgtgtgata agatatcgcg gccgctctag accaggcgcc tggatccgcc accatgccac 4920  
 tctgggtgtt cttctttgtg atcctcacc tcagcaacag ctcccactgc tccccacctc 4980  
 cccctttgac cctcaggatg cggcggtatt atgcagatgc catctcacc aacagctacc 5040  
 10 ggaaggtgct ggcccagctg tccgcccga aggccctcca ggacatcatg agcaggtaga 5100  
 gatccagatc t 5111

15 <210> 56  
 <211> 3327  
 <212> DNA  
 <213> Artificial Sequence

20 <220>  
 <223> Description of Artificial Sequence:  
 pGHRH1-29Yala1522SK construct

25 <400> 56  
 ggtaccgagc tcttacgcgt gctagcccg gctcgagatc tgcgatctaa gtaagcttgc 60  
 caccatgcc a ctctgggtgt tcttctttgt gatcctcacc ctacagcaaca gctcccactg 120  
 ctccccacct cccctttga cctcaggat gggcggtat tatgcagatg ccatcttcac 180  
 caacagctac cggaaggtgc tggcccagct gtccgccgc aaggccctcc aggacatcat 240  
 30 gagcaggtag tctagagtcg gggcgcccg ccgcttcgag cagacatgat aagatacatt 300  
 gatgagtttg gacaaaccac aactagaatg cagtgaataa aatgctttat ttgtgaaatt 360  
 tgtgatgcta ttgctttatt tgttaaccatt ataagctgca ataaacaagt taacaacaac 420  
 aattgcattc attttatgtt tcagggttcag ggggaggtgt gggaggtttt ttaaagcaag 480  
 taaaacctct acaaatgtgg taaaatcgat aaggatccgt cgaccgatgc cttgagagc 540  
 35 cttcaaccca gtcagctcct tccggtgggc gggggcatg actatcgtcg ccgcacttat 600  
 gactgtcttc tttatcatgc aactcgtagg acagggtgcc gcagcgtctt tccgcttctc 660  
 cgctcactga ctcgctgcgc tcggtcgttc ggtgcggcg agcggtatca gctcactcaa 720  
 aggcggtaat acggttatcc acagaatcag gggataacgc aggaagaac atgtgagcaa 780  
 40 aaggccagca aaaggccagg aaccgtaaaa aggcgcggtt gctggcggtt tcccataggc 840  
 tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagaggtag cgaaacccga 900  
 caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc 960  
 cgaccctgac gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt 1020  
 ctcaatgctc acgctgtagg tatctcagtt cgggttaggt cgttcgctcc aagctgggct 1080  
 45 gtgtgcacga acccccggtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg 1140  
 agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta 1200  
 gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct 1260  
 acactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa 1320  
 50 gagtggtag ctcttgatcc ggcaacaaa ccaccgctgg tagcgggtgt tttttgttt 1380  
 gcaagcagca gattacgcgc agaaaaaag gatctcaaga agatcctttg atcttttcta 1440  
 cggggtctga cgtcagtg gacgaaaact caggttaagg gatlttggtc atgagattat 1500  
 caaaaaggat cttcacctag atccttttaa attaaaaatg aagtttttaa tcaatctaaa 1560  
 55 gtatatatga gtaaaacttg tctgacagtt accaatgctt aatcagtgag gcacctatct 1620  
 cagcgatctg tctatttcgt tcatccatag ttgcctgact ccccgctgtg tagataacta 1680

# EP 1 205 551 A1

5 cgatacggga gggettacca tctggcccca gtgctgcaat gataccgcga gacccacgct 1740  
 caccggctcc agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg 1800  
 gtcttgcaac tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa 1860  
 gtagttcgcc agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt 1920  
 cacgctcgtc gtttgggatg gcttcattca gctccggttc ccaacgatca aggcgagtta 1980  
 catgatcccc catgtttgtc aaaaaagcgg ttagctcctt cggtcctcgg atcgttgtca 2040  
 10 gaagtaagtt ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta 2100  
 ctgtcatgcc atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct 2160  
 gagaatagtg tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataatacgg 2220  
 cgccacatag cagaacttta aaagtgtcga tcattggaaa acgttcttcg gggcgaaaa 2280  
 tctcaaggat cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact 2340  
 15 gatcttcagc atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa 2400  
 atgccgcaaa aaagggaata agggcgacac ggaaatgttg aatactcata ctcttctttt 2460  
 ttcaatatta ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat 2520  
 gtatttagaa aaataaacia ataggggttc cgcgcacatt tccccgaaaa gtgccacctg 2580  
 20 acgcgccctg tagcggcgca ttaagcgcgg cgggtgtggt ggttacgcgc agcgtgaccg 2640  
 ctacacttgc cagcgcacct ggcgccgctc ctttcgcttt cttcccttcc tttctcgcca 2700  
 cgttcgcggc ctttccccgt caagctctaa atcggggggt cccttttaggg ttccgattta 2760  
 gtgctttacg gcacctcgac cccaaaaaac ttgattaggg tgatggttca cgtagtgggc 2820  
 catgcacctg atagacgggt tttcgccctt tgacgttggg gtccacgttc tttaatagt 2880  
 25 gactcttggt ccaaaactga acaacactca accctatctc ggtctattct tttgatttat 2940  
 aagggttttt gcgattttcg gctatttggg taaaaaatga gctgatttaa caaaaattta 3000  
 acgcgaattt taacaaaata ttaacgttta caatttccca ttcgccattc aggcgtgcga 3060  
 actgttggga agggcgatcg gtgcgggcct cttcgctatt acgccagccc aagctaccat 3120  
 30 gataagtaag taatattaag gtacgggagg tacttggagc ggccgcaata aaatatcttt 3180  
 attttcatta catctgtgtg ttgggttttt gtgtgaatcg atagtactaa catacgctct 3240  
 ccatcaaaac aaaacgaaac aaaacaaact agcaaaatag gctgtcccca gtgcaagtgc 3300  
 aggtgccaga acatttctct atcgata 3327

35

<210> 57

<211> 3954

<212> DNA

40

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

45

pGHRH1-29Yala1522SK construct

<400> 57

50

ggtaccatcg ctggggagct gggggagggg tcgccttctt gccctaccca ggactccggg 60  
 tgcgacgcgt cctctatctc tcagccccc caccactcca ccacttggac acgtctcctt 120  
 cctccctgga gtgcgtctag aggggtttgg ggtctgagta aagaaccgga agtagggata 180  
 cagtgtggcg gcaccttcca gaggccccgg gcgcagggtg gaccggggcg gggcgggccc 240  
 cggacagggt cagccccagg cgcaggcgca ctgcgcctc ccggcgccag cgggtgaacct 300  
 cgccccaccc cagcccttcc ggggggcagc tgggcggggt cgggaggggc ccaccagccc 360  
 55 gggagacact ccatatacgg ccaggccccc tttaacctgg ctccggccag gccgctcctt 420  
 ctttgggtcag cacaggggac ccgggcgggg gccccaggcc ctaaccgccg gggggagggg 480

EP 1 205 551 A1

gctccagtgc ccaacaccca aatatggctc gagaagggga ggcacattcc agtgaggcgg 540  
 ctccggggga gaaccgcgg gctatataaa acctgagcgt ggggaccagc ggccaccgca 600  
 5 gcgagacagc ccgagagaag cctcgettc ccccgcggc gaccagggcc ccagccggag 660  
 agcagcaggt gtagccacca agcttgccac catgccactc tgggtgttct tctttgtgat 720  
 cctcaccctc agcaacagct cccactgctc cccacctccc cctttgacct tcaggatgcg 780  
 gcggtattat gcagatgcc tcttcaccaa cagctaccgc aaggtgctgg ccagctgtc 840  
 10 cgcgcgcaag gccctccagg acatcatgag caggtagtct agagtccggg cgcccgccg 900  
 cttcgagcag acatgataag atacattgat gaggtttgac aaaccacaa tagaatgcag 960  
 tgaaaaaat gctttatttg tgaaatttgt gatgctattg ctttatttgt aaccattata 1020  
 agctgcaata aacaagttaa caacaacaat tgcattcatt ttatgtttca gggtcagggg 1080  
 gaggtgtggg aggtttttta aagcaagtaa aacctctaca aatgtggtaa aatcgataag 1140  
 15 gatccgtcga ccgatgccct tgagagcctt caaccagtc agctccttcc ggtgggccc 1200  
 ggcgatgact atcgctgcgc cacttatgac tgtcttctt atcatgcaac tcgtaggaca 1260  
 ggtgcggca gcctccttc gcttcctgc tcaactgactc gctgcgctcg gtcgttcggc 1320  
 tgccgagcag ggtatcagct cactcaaagg cggtaatacg gttatccaca gaatcagggg 1380  
 20 ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa ggccaggaa cgtaaaaag 1440  
 ccgcgttgct ggcgttttcc cataggtctc gccccctga ccgagcatcac aaaaatcgac 1500  
 gctcaagtca gaggtggcga aaccgcagc gactataaag ataccaggcg ttccccctg 1560  
 gaagctccct cgtgcgctct cctgttcoga ccctgccgt taccggatac ctgtccgcct 1620  
 25 ttctcccttc gggaagcgtg gcgctttctc aatgctcac ctgtaggat ctgagttcgg 1680  
 tgtaggctgt tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag ccgaccgct 1740  
 gcgccttata ccgtaactat cgtcttgagt ccaaccggg aagacacgac ttatcgccac 1800  
 tggcagcagc cactggtaac aggattagca gagcgaggta tgtaggcggg gctacagagt 1860  
 tcttgaagt gtggcctaac tacggctaca ctagaaggac agtatttggg atctgcctc 1920  
 30 tgctgaagcc agttacctc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca 1980  
 ccgctggtag ccgtgtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat 2040  
 ctcaagaaga tcttttgatc tttctacgg ggtctgacgc tcagtggaa gaaaactcac 2100  
 gtaagggat tttggtcatg agattatcaa aaaggatctt caccatagatc cttttaaatt 2160  
 35 aaaaatgaag ttttaaatca atctaaagta tatatgagta aacttggtct gacagttacc 2220  
 aatgcttaat cagtgaggca cctatctcag cgatctgtct atttcgttca tccatagttg 2280  
 cctgaactcc cgtcgtgtag ataactacga tacgggaggg cttaccatct ggccccagt 2340  
 ctgcaatgat accgcgagac ccacgctcac cggctccaga tttatcagca ataaaccagc 2400  
 cagccggaag ggccgagcgc agaagtgtc ctgcaacttt atccgcctcc atccagtcta 2460  
 40 ttaattgttg ccgggaagct agagtaagta gttcgccagt taatagtttg cgaacggtg 2520  
 ttgccattgc tacaggcatc gtggtgtcac gctcgtcgtt tggatggct tcattcagct 2580  
 ccggttccca acgatcaagg cgagttacat gatccccat gttgtgcaaa aaagcggtta 2640  
 gctccttcgg tctccgacg gttgtcagaa gtaagttggc ccgagtggtt tcaactcatg 2700  
 45 ttatggcagc actgcataat tctcttactg tcatgccatc cgtaaagatgc ttttctgtga 2760  
 ctggtgagta ctcaaccaag tcattctgag aatagtgtat gcggcgaccg agttgctctt 2820  
 gcccggcgtc aatacgggat aataccgcgc cacatagcag aactttaaaa gtgtcatca 2880  
 ttgaaaaacg ttcttcgggg cgaaaaactc caaggatctt accgctgttg agatccagtt 2940  
 50 cgatgtaacc cactcgtgca cccaactgat cttcagcatc ttttactttc accagcgttt 3000  
 ctgggtgagc aaaaacagga aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga 3060  
 aatgttgaat actcatactc ttcttttttc aatattattg aagcatttat cagggttatt 3120  
 gtctcatgag cggatacata tttgaatgta tttagaaaaa taaacaaata ggggttcgc 3180  
 gcacatttcc ccgaaaagtg ccacctgacg cgcctgtag cggcgatta agcgcggcgg 3240  
 55 gtgtgggtgt tacgcgcagc gtgaccgcta cacttgccag cgcctagcg cccgctctt 3300  
 tcgctttctt ccttctctt ctcgccacgt tcgcggctt tcccgtcaa gctctaaatc 3360

# EP 1 205 551 A1

5 gggggctccc tttaggggtc cgatttagtg ctttacggca cctcgacccc aaaaaacttg 3420  
 attaggggtga tggttcacgt agtgggccaat cgccctgata gacgggtttt cgccctttga 3480  
 cgttggagtc caggttcttt aatagtggac tcttgttcca aactggaaca aactcaacc 3540  
 ctatctcggg ctattctttt gatttataag ggattttgoc gatttcggcc tattgggttaa 3600  
 aaaatgagct gatttaacaa aaatttaacg cgaattttta caaaatatta acgtttacaa 3660  
 tttcccatte gccattcagg ctgcgcaact gttgggaagg gcgacgggtg cgggcctctt 3720  
 10 cgctattacg ccagcccaag ctaccatgat aagtaagtaa tattaaggta cgggaggtac 3780  
 ttggagcggc cgcaataaaa tatctttatc ttcattacat ctgtgtgttg gttttttgtg 3840  
 tgaatcgata gtactaacat acgtctctcca tcaaaacaaa acgaaacaaa acaaactagc 3900  
 aaaataggct gtccccagtg caagtgcagg tgccagaaca tttctctatc gata 3954

15

<210> 58

<211> 5283

<212> DNA

20

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

25

pGHRH1-29Yala1522SK2014 construct

<400> 58

30

ggtaccgcta taggagagaa aagagctgca ctgagcacc ccttcccct ttaaattgtca 60  
 acagattagg agtcagtgaa tgacagcaca cctcttgcta ccttagagac caaaatttaa 120  
 gctactcccc ttaagctata gctagagtgc acctgccagt gtctttagtc ccacatgatg 180  
 gaacaggacc caagggtattg aagatggaac atagtatttc attcatcctc taatttaaaa 240  
 agctggatat gctgtacagc agaaattgac ggaacaatgt aaatcaacta taacagaaga 300  
 aataaaaaacc tggggggaaa gaagctgact atgaaacccc aggagctttc tacatgggcc 360  
 35 tggactcacc aaactcttta ttttgaatg gacttctgac attttttagga agggctgtcc 420  
 tgatgtgggc tatagaagag ggtttcacat gcttcttcaa gaggaccac actgtccag 480  
 ttgctgagtc ccaccaccag atgctagtgg cagctatttg gggaaactt aggcactaca 540  
 aaaaaatgag tgattccatt ctggctcaca ccataccct gatgtacccc ttaaagcatg 600  
 tcaactgagt catcacagaa aattgtttcc cctgtgcctt ccacaacaag gttagagctg 660  
 40 tcttggggc caggggaagg gggcagggag tgagaagcac caactggata acctcctctg 720  
 accccactc caccctacca taagtagatc caaatcctc tagaaaatta ggaaggcata 780  
 tccccatata tcagcgatat aaatagaact gcttcagcgc tctggtagac ggtgactctc 840  
 caagggtggc tgggaggcag cctggccttg gctgggcac gtctctaaa tagaaagatg 900  
 45 aacttgttca gcctttccag aaggaaaact gctgccagc ctacagtga acgtccttgt 960  
 ctccatctg gaggaagcac ggtgacata tcactagta agggcacctc tctgtttcca 1020  
 cctccaggtc gaggggtgtg accttactt ctacgctca agggaggac actcaacccc 1080  
 caaaaaagac atgagggcgc tcagctcggc ccaccgcacc ccggaccgga gccgtcacc 1140  
 ccgaaattc actcccttca caagccccc agcgcgttct ctggtgcgga ctgctccggg 1200  
 50 gccctggctt tgtgcccagc gttgtcagag ccaccgccct gagcctgtcc ccgggagccc 1260  
 cgcgcctcct ccaccgcgc cgtctctcgc ccccgcggcc agttgtctgc ccgagacag 1320  
 ctgcgcgccc tcccgtgcc ggtggccctc tccggtgggg gtggggaccg acagggctcag 1380  
 cctccggat ccggggcgct ccgggtagcg gggagaagt atcgtgggg agctggggga 1440  
 55 ggggtcgcct tctgcctca ccaggactc cgggtgcgac cgtcctcta tctctccagc 1500  
 ccaccaccac tccaccactt ggacacgtct cctcctccc tggagtcgct ctgaggggtt 1560

EP 1 205 551 A1

tgggggtctg agtaaagaac ccgaagtagg gatacagtgt ggccggcacct tccagaggcc 1620  
 ccggggcgag ggtagaccgg ggccggggcg cccggcgaca ggtgcagccc caggcgaggg 1680  
 5 cgcactcgcg cctcccgcg caggcggtga acctcgcccc accccagccc ctccgggggg 1740  
 cagctggggc gggtcgggag gggcccacca gcccgggaga cactccatat acggccaggc 1800  
 ccgctttacc tgggtcccg ccaggccgct ccttctttgg tcagcacagg ggaccggggc 1860  
 gggggcccag gccgctaacc cgccggggga gggggctcca gtgcccaaca cccaaatatg 1920  
 gctcgagaag gggagcgaca ttccagttag gcggtcggg ggagaaacc gcgggctata 1980  
 10 taaaacctga gcgtggggac cagcgcccaa gcttgccacc atgccactct ggggtgttctt 2040  
 ctttgtgac ctcacctca gcaacagctc cactgctcc ccacctccc ctttgacctt 2100  
 caggatgcgg cggattattg agatgccat cttaccaac agctaccgga aggtgctggc 2160  
 ccagctgtcc gcccgcaagg ccctccagga catcatgagc aggtagtcta ggtcggggc 2220  
 15 ggccggccgc ttcgagcaga catgataaga tacattgatg agtttgga aaccacaact 2280  
 agaatgcagt gaaaaaatg cttattttgt gaaattttgt atgctattgc tttatttgt 2340  
 accattataa gctgcaataa acaagttaac aacaacaatt gcattcattt tatgtttcag 2400  
 gttcaggggg aggtgtggga ggttttttaa agcaagtaaa acctctaca atgtggtaaa 2460  
 20 atcgataagg atccgtcgac cgatgccctt gagagcctt aaccagtcga gctccttcg 2520  
 gtggcgcgcg ggcatgacta tcgtcgccgc acttatgact gtcttcttta tcatgcaact 2580  
 cgtaggacag gtgccggcag cgtctcttcg ctctctcgct cactgactcg ctgcgctcgg 2640  
 tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag 2700  
 aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccagggaacc 2760  
 25 gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg ccccccgtac gagcatcaca 2820  
 aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt 2880  
 tcccccttg aagctccctc gtgcgctctc ctgttccgac cctgcgctt accggatacc 2940  
 tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca atgctcacgc tgtaagttatc 3000  
 30 tcagttcggt gtaggtcggt cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc 3060  
 ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caaccggta agacacgact 3120  
 tatcgccact ggacgcagcc actggtaaca ggattagcag agcgaggat gtaggcggtg 3180  
 ctacagagtt ctggaagtgg tggcctaact acggctacac tagaaggaca gtatttggt 3240  
 tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca 3300  
 35 aacaaaccac cgtggttagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa 3360  
 aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaaag 3420  
 aaaactcag ttaagggtatt ttggtcatga gattatcaa aaggatcttc acctagatcc 3480  
 ttttaaatta aaaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg 3540  
 40 acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcac 3600  
 ccatagttgc ctgactcccc gtctgttaga taactacgat acgggagggc ttaccatctg 3660  
 gccccagtcg tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa 3720  
 taaaccagcc agccggaagg gccgagcgca gaagtgttcc tgcaacttta tccgcctcca 3780  
 tccagtctat taattgttgc cgggaagcta gagtaagtag ttccgagtt aatagtttgc 3840  
 45 gcaacgttgt tgccattgct acaggcatcg tgggtgcacg ctgctgcttt ggtatggctt 3900  
 cattcagctc cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa 3960  
 aagcggttag ctcttcgggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat 4020  
 cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct 4080  
 50 tttctgtgac tgggtgagtag tcaaccaagt cattctgaga atagtgtatg cggcgaccga 4140  
 gttgctcttg cccggcgtca atacgggata ataccgccc acatagcaga actttaaaag 4200  
 tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga 4260  
 gatccagttc gatgtaaccc actcgtgcac ccaactgac ttcagcatct tttactttca 4320  
 ccagcgtttc tgggtgagca aaaacaggaa gcaaaaatgc cgcaaaaaag ggaataaggg 4380  
 55 cgacacggaa atgttgaata ctcatactct tcttttttca atattattga agcattttac 4440

# EP 1 205 551 A1

5 aggggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag 4500  
 ggggtccgcg cacatttccc cgaaaagtgc cacctgacgc gccctgtagc ggcgcatata 4560  
 gcgcggcggg tgtggtggtt acgcgcagcg tgaccgctac acttgccagc gccctagcgc 4620  
 ccgtcccttt cgttttcttc ccttccttcc tcgccacggt cgcgcgcttt ccccgtaag 4680  
 ctctaaatcg ggggctccct ttaggggtcc gatttagtgc ttacggcac ctgcaccca 4740  
 aaaaactlga ttaggggtgal gggtcacgta gtgggccatc gccctgatag acgggttttc 4800  
 10 gccctttgac gtlggagtcc acgttcttta atagtggact cttgttccaa actggaacaa 4860  
 cactcaacc cttctcggtc tattcttttg atttataagg gattttgccg atttcggcct 4920  
 attggtttaa aaatgagctg atttaacaaa aatttaacgc gaattttaac aaaatattaa 4980  
 cgtttacaat tcccattcg ccattcaggc tgcgcaactg ttgggaaggc cgtcgggtgc 5040  
 gggcctcttc gctattacgc cagcccaagc taccatgata agtaagtaat attaaggtag 5100  
 15 gggaggtagt tggagcgcc gcaataaaat atctttattt tcattacatc tgtgtgttg 5160  
 tttttgtgt gaatcgatag tactaacata cgtctccat caaaacaaaa cgaacaaaa 5220  
 caaactagca aaataggctg tcccagtcg aagtcaggt gccagaacat ttctctatcg 5280  
 ata 5283

20

<210> 59

<211> 5188

<212> DNA

25

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

30

pGHRH1-44YWTMV construct

<400> 59

35

gctgtgccc ctagttgcca gccatctgtt gtttgccct ccccgctgc ttccttgacc 60  
 ctggaagggt ccaactccac tgcctttcc taataaaatg aggaaattgc atcgattgt 120  
 ctgagtaggt gtcattctat tctgggggtt ggggtgggc aggacagcaa gggggaggat 180  
 tgggaagaca atagcaggca tgcctgggat gcggtgggt ctatgggtac ccagggtgct 240  
 aagaattgac ccggttcttc ctgggccaga aagaagcagg cacatccct tctctgtgac 300  
 acaccctgtc cagcccccgt gttcttagtt ccagccccc tcataggaca ctcatagctc 360  
 40 aggagggctc cgccttcaat cccaccgct aaagtacttg gagcggtctc tccctccctc 420  
 atcagccccc caaaccaaac ctagcctcca agagtggga gaaattaaag caagataggc 480  
 tattaagtgc agagggagag aaaatgcctc caacatgtga ggaagtaat agagaaatca 540  
 tagaatttct tccgcttctc cgtcactga ctcgctgcgc tcggtcgttc ggctggggcg 600  
 45 agcggtatca gctcaactca aggcggtaat acggttatcc acagaatcag gggataacgc 660  
 aggaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggcgcggtt 720  
 gctggcggtt tcccataggc tccgcccccc tgacgagcat cacaacaaatc gacgctcaag 780  
 tcagagggtg cgaacccga caggactata aagataaccg gcgtttcccc ctggaagctc 840  
 cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cctttctccc 900  
 50 ttcgggaagc gtgcgcttt ctcataagct acgctgtagg tatctcagtt cgggtgtagg 960  
 cgttcgctcc aagctgggt gtgtgcacga acccccgtt cagcccgacc gctgcgctt 1020  
 atccggtaac tctcgtcttg agtccaacc ggtaagacac gacttatcgc cactggcagc 1080  
 agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 1140  
 55 gtggtggcct aactacggt aactagaag aacagtattt ggtatctgc ctctgctgaa 1200  
 gccagttacc ttcgaaaaa gagttgtag cctctgatcc ggcaacaaaa ccaccgctg 1260

EP 1 205 551 A1

tagcgggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 1320  
agatcctttg atcttttcta cggggtctga cgtcagtgag aacgaaaact cacgttaagg 1380  
5 gatttttggtc atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg 1440  
aagtttttaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgctt 1500  
aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag ttgcctgact 1560  
cggggggggg gggcgctgag gtctgcctcg tgaagaagggt gttgctgact cataccaggc 1620  
ctgaatcgcc ccatcatcca gccagaaagt gagggagcca cggttgatga gagctttgtt 1680  
10 gtaggtggac cagtttgtga ttttgaactt ttgctttgcc acggaacggg ctgcgttgct 1740  
gggaagatgc gtgatctgat ccttcaactc agcaaaagt ttgatttatt aacaaagccg 1800  
ccgtcccgct aagtcagcgt aatgctctgc cagtgttaca accaattaac caattctgat 1860  
tagaaaaact catcgagcat caaatgaaac tgcaatttat tcatatcagg attatcaata 1920  
15 ccatattttt gaaaaagccg tttctgtaat gaaggagaaa actcaccgag gcagttccat 1980  
aggatggcaa gatcctggta tgggtctgcg attccgactc gtccaacatc aatacaacct 2040  
attaatttcc cctcgtcaaa aataaggta tcaagtgaga aatcaccatg agtgacgact 2100  
gaatccgggt agaatggcaa aagcttatgc atttctttcc agacttgctc aacaggccag 2160  
20 ccattacgct cgtcatcaaa atcactcgca tcaaccaaac cgttattcat tctgtattgc 2220  
gctgagcga gacgaaatac gcgatcgctg ttaaaaggac aattacaaac aggaatcgaa 2280  
tgcaaccggc gcaggaacac tgccagcgca tcaacaatat ttccacctga atcaggatat 2340  
tcttctaata cctggaatgc tgttttcccg gggatcgag tggtagtaaa ccatgcatca 2400  
tcaggagtac ggataaaatg cttgatgggc ggaagaggca taaattccgt cagccagttt 2460  
25 agtctgacca tctcatctgt aacatcattg gcaacgctac ctttgccatg ttccagaaac 2520  
aactctggcg catcgggctt cccatataat cgtatagattg tgcacctga ttgcccgaca 2580  
ttatcgcgag ccattttata cccatataaa tcagcatcca tgttggaatt taatcgcggc 2640  
ctcgagcaag acgtttcccg ttgaatatgg ctcataacac ccttgtatt actgtttatg 2700  
30 taagcagaca gttttattgt tcatgatgat atatttttat cttgtgcaat gtaacatcag 2760  
agattttgag acacaacgtg gctttccccc ccccccatt attgaagcat ttatcagggt 2820  
tattgtctca tgagcggata catatttgaa tgtattttaga aaaataaaca aatagggggt 2880  
ccgcgcacat ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 2940  
ttaacctata aaaataggcg tatcacgagg ccttttcgtc ctgcgcgctt tccgtgatga 3000  
35 cgggtgaaaac ctctgacaca tgcagctccc ggagacggtc acagcttgct tctaagcgga 3060  
tgccgggagc agacaagccc gtcaggggcg gtcagcgggt gttggcgggt gtcggggctg 3120  
gcttaactat gcggcatcag agcagattgt actgagagtg caccatatgc ggtgtgaaat 3180  
accgcacaga tgcgtaagga gaaaataccg catcagattg gctattggcc attgcatacg 3240  
40 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgccatgt 3300  
tgacattgat tatcgactag ttattaatag taatcaatta cggggtcatt agttcatagc 3360  
ccatatatgg agttcccggt tacataactt acggtaaatg gccgcctgg ctgaccgcc 3420  
aacgaccccc gccattgac gtcaataatg acgtatgttc ccatagtaac gccaataggg 3480  
45 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt gccagtacat 3540  
caagtgtatc atatgccaa gacgccccct attgacgtca atgacggtaa atggcccgcc 3600  
tggcattatg ccagctacat gacottatgg gactttccta cttggcagta catctacgta 3660  
ttagtcacgc ctattacat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag 3720  
cggtttgact cagggggatt tccaagtctc caccocattg acgtcaatgg gagtttggtt 3780  
50 tggcaccaaa atcaacggga ctttccaaaa tgtcgttaaa actccgcccc attgacgcaa 3840  
atgggcggta ggcggtgacg gtgggaggtc tatataagca gagctcgttt agtgaaccgt 3900  
cagatcgctt ggagacgcca tccacgctgt tttgacctcc atagaagaca cggggaccga 3960  
tccagcctcc gcggccggga acggtgcatt ggaacgcgga ttccccgtgc caagagtac 4020  
55 gtaaglacgc cctatagact ctataggcac accccttgg ctcttatgca tgcatactg 4080  
tttttggtt ggggcctata caccoccgct tcttatgct ataggtgatg gtatagctta 4140

# EP 1 205 551 A1

gcctataggt gtgggttatt gaccattatt gaccactccc ctattggtga cgatactttc 4200  
 cattactaat ccataacatg gctctttgcc acaactatct ctattggcta tatgccaaata 4260  
 5 ctctgtcctt cagagactga cacggactct gtattttttac aggatgggggt cccattttatt 4320  
 atttacaaat tcacatatac aacaacgcgc tccccgtgc ccgcagtttt tattaacat 4380  
 agcgtgggat ctccacgcga atctcgggta cgtgttccgg acatgggctc ttctccggta 4440  
 ggcggggagc ttccacatcc gagecctggg cccatgcctc cagcggctca tggctcgtcg 4500  
 gcagctcctt gctcctaaca gtggaggcca gacttaggca cagcacaatg cccaccacca 4560  
 10 ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc tgaaaatgag cgtggagatt 4620  
 gggctcgcac ggctgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca 4680  
 gctgagttgt tgtattctga taagagtcag aggtaactcc cgttgcggtg ctgttaacgg 4740  
 tggagggcag tgtagtctga gcagtactcg ttgctgcgcg gcgcgccacc agacataata 4800  
 15 gctgacagac taacagactg ttcttttcca tgggtctttt ctgcagtcac cgtcgtcgac 4860  
 acgtgtgac agatctcgcg gccgctctag accaggcgcc tggatccgcc accatgccac 4920  
 tctgggtggt ctctctttgt atctcacc ccagcaacag ctcccactgc tccccactc 4980  
 cccctttgac cctcaggatg cggcgggtatt atgcagatgc catcttccac aacagctacc 5040  
 20 ggaaggtgct gggccagctg tccgccgcga agctgctcca ggacatcatg agcaggcagc 5100  
 agggagagag aaaccaagag caaggagcaa gggtcgggct ttgaagatct tagtagtagt 5160  
 aggcggccgc tctagaggat ccagatct 5188  
  
 25 <210> 60  
 <211> 5254  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <223> Description of Artificial Sequence:  
 pGHRH1-44WTGHpep construct  
 35  
 <400> 60  
 gctgtgcctt ctagttagca gccatctggt gtttgccctt cccccgtgc ttctctgacc 60  
 ctggaagggt ccactccac tgtcttttcc taataaaatg aggaaattgc atcgattgt 120  
 ctgagtaggt gtcattctat tctgggggtt ggggtggggc aggcagcaca gggggaggat 180  
 40 tgggaagaca atagcaggca tgcctgggat gcggtgggct ctatgggtac ccagggtgctg 240  
 aagaattgac ccggttctc ctggggcaga aagaagcagg cacatccctt tctctg-gac 300  
 acaccctgtc cagcctctg gttcttagtt ccagcccccac tcataggaca ctcatagctc 360  
 aggagggctc cgccttcaat cccacccgct aaagtacttg gagcgtctc tccctccctc 420  
 45 atcagccac caaaccacac ctagcctcca agagtgggaa gaaattaaag caagataggc 480  
 tattaagtgc agagggagag aaaatgcctc caacatgtga ggaagtaatg agagaaatca 540  
 tagaatttct tccgttctt cgtcactga ctgcgtgcgc tgggtcgttc ggctgcggcg 600  
 agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc 660  
 aggaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggcgcggtt 720  
 50 gctggcggtt ttccataggc tccgcccccc tgacgagcat caaaaaatc gacgtcaag 780  
 tcagaggtgq cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc 840  
 cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cttttctccc 900  
 ttgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cgggtgtaggt 960  
 55 cgttcgctcc aagctgggct gtgtgcacga acccccgtt cagcccgacc gctgcgcctt 1020  
 atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc 1080



EP 1 205 551 A1

5 agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 1140  
 gtgggtggcct aactacggct acactagaag aacagtatct ggtatctgcg ctctgctgaa 1200  
 gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg 1260  
 tagcgggtgg ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 1320  
 agatcccttg atcttttcta cggggtctga cgcctcagtg aacgaaaact cacgttaagg 1380  
 gatttttggtc atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg 1440  
 10 aagllttaaa tcaatctaaa gtatatatga gtaaaacttg tctgacagtt accaatgctt 1500  
 aatcagtgag gcacctatct cagcgatctg tctatttogt tcatocatag ttgcctgact 1560  
 cggggggggg gggcgcctgag gtctgcctcg tgaagaagggt gttgctgact cataccaggc 1620  
 ctgaatcgcc ccatacatca gccagaaagt gagggagcca cggttgatga gagctttgtt 1680  
 gtaggtggac cagttgggtga ttttgaactt ttgctttgcc acggaacggg ctgctgttgc 1740  
 15 gggaagatgc gtgatctgat ccttcaactc agcaaaagt cgatttatc aacaaagccg 1800  
 ccgtcccgct aagtcagcgt aatgctctgc cagtgttaca accaattaac caattctgat 1860  
 tagaaaaact catcgagcat caaatgaaac tgcaatttat tcatatcagg attatcaata 1920  
 ccataatttt gaaaaagccg tttctgtaat gaaggagaaa actcaccgag gcagttccat 1980  
 20 aggatggcaa gatcctggta tcgggtctgcg attccgactc gtccaacatc aatacaacct 2040  
 attaatttcc cctcgtcaaa aataaggtta tcaagtgaga aatcaccatg agtgacgact 2100  
 gaatccgggtg agaattggcaa aagcttatgc atttctttcc agacttggtc aacaggccag 2160  
 ccattacgct cgtcatcaaa atcactcgca tcaaccaaac cgttatccat tctgtattgc 2220  
 25 gctgagcgga gacgaaatac gcgatcgtg ttaaaaggac aattacaaac aggaatcgaa 2280  
 tgcaaccggc gcaggaacac tgccagcgca tcaacaatat ttccacctga atcaggatat 2340  
 tcttctaata cctggaatgc tgttttcccg gggatcgag tggtagtaaa ccatacatca 2400  
 tcaggagtac ggataaaatg cttgatggtc ggaagaggca taaattccgt cagccagttt 2460  
 agtctgacca tctcatctgt aacatcattg gcaacgctac ctttgccatg ttccagaaac 2520  
 30 aactctggcg catcgggctt ccatacaat cgaatagatt tgcacctga ttgcccagca 2580  
 ttatcgcgag ccattttata ccataataaa tcagcatcca tgttgaatt taatcgcggc 2640  
 ctcgagcaag acgtttcccg tgaatatgg ctcataacac cccttgatt actgtttatg 2700  
 taagcagaca gttttattgt tcatgatgat atatttttat cttgtgcaat gtaacatcag 2760  
 35 agattttgag acacaacgtg gctttccccc ccccccatt attgaagcat ttatcagggg 2820  
 tattgtctca tgagcggata catatttgaa tgtatttaga aaaataaaca aataggggtt 2880  
 ccgcgcacat tccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 2940  
 ttaacctata aaaataggcg tatcacgagg cctttctgct ctcgcgcgtt tgggtgatga 3000  
 40 cggtgaaaac ctctgacaca tgcagctccc ggagacggtc acagcttgct tgaagcggg 3060  
 tgccgggagc agacaagccc gtcaggcgcc gtcagcgggt gttggcgggt gtcggggctg 3120  
 gcttaactat gcggcatcag agcagattgt actgagagtg caccatatgc ggtgtgaaat 3180  
 accgcacaga tgcgtaagga gaaaataccg catcagattg gctattggcc attgcatacg 3240  
 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgccatgt 3300  
 45 tgacattgat tattgactag ttattaatag taatcaatta cggggtcatt agttcatagc 3360  
 ccataatatg agttccgcgt tacataactt acggtaaatg gccgcctgg ctgaccgccc 3420  
 aacgaccccc gccattgac gcaataatg acgtatgttc ccatagtaac gccaataggg 3480  
 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgccactt ggcagtacat 3540  
 50 caagtgtatc atatgccaa gacgcccct attgacgtca atgacggtaa atggcccgc 3600  
 tggcattatg ccagtlacat gaccttatgg gaccttecta cttggcagta catctacgta 3660  
 ttagtcatcg ctattacat ggtgatgcgg ttttgccagt acatcaatgg gcgtgatag 3720  
 cggtttgact cacggggatt tccaagtct caccocattg acgtcaatgg gagtttgttt 3780  
 55 tggcaccaaaa atcaacggga ctttccaaaa tgcgtaaca actccgcccc attgacgcaa 3840  
 atgggcggga ggcgtgtac gggggaggtc tatataagca gagctcgttt agtgaaccgt 3900  
 cagatcgctt ggagacgcca tccacgtgtt tttgacctcc atagaagaca cggggaccga 3960

# EP 1 205 551 A1

tccagcctcc ggggcccggga acggtgcatt ggaacgcgga ttccccgtgc caagagtgc 4020  
 gtaagtaccg cctatagact ctataggcac acccctttgg ctcttatgca tgctatactg 4080  
 5 tttttggctt ggggcctata ccccccgct tccttatgct ataggatgat gtatagctta 4140  
 gcctataggt gtgggttatt gaccattatt gaccactccc ctattgggtga cgatactttc 4200  
 cactactaat ccataacatg gctctttgcc acaactatct ctattggcta tatgccaaata 4260  
 ctctgtcctt cagagactga caccgactct gtatttttac aggatggggt ccatttatt 4320  
 10 atttacaaat tcacatatac aacaacgcg tccccgtgc ccgcagtttt tattaacat 4380  
 agcgtgggat ctccacgcga atctcgggta cgtgttccgg acatgggctc ttctccggt 4440  
 gggcgggagc ttccacatcc gagccctggt cccatgcctc cagcggctca tggctcgtcg 4500  
 gcagctcctt gctcctaaca gtggaggcca gacttaggca cagcacaatg cccaccacca 4560  
 ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc tgaaaatgag cgtggagatt 4620  
 15 gggctcgcac ggctgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca 4680  
 gctgagttgt tgtattctga taagagtcag aggtactcc cgttgcggtg ctgttaacgg 4740  
 tggagggcag tgtagtctga gcagtactcg ttgctgccgc gcgcgccacc agacataata 4800  
 gctgacagac taacagactg ttcttttcca tgggtctttt ctgcagtcac cgtcgtcgac 4860  
 20 acgtgtgatc agatatcgcg gccgtcttag accaggcgcc tggatccgcc accatgccac 4920  
 tctgggtgtt cttctttgtg atcctcacc tcagcaacag ctccactgc tccccacctc 4980  
 cccctttgac cctcaggatg cggcggtatt atgcagatgc catcttcacc aacagctacc 5040  
 ggaaggtgct gggccagctg tccgccgca agctgctcca ggacatcatg agcaggcagc 5100  
 25 agggagagag aaaccaagag caaggagcaa ggggtcggct tgggcggaaa gtagaacgt 5160  
 ttctgcgtat tgtacagtgt cgtagcgtag aaggagctg tgggttttga agatcttagt 5220  
 agtagtaggc ggccgctcta gaggatccag atct 5254

30 <210> 61  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

35 <220>  
 <223> Description of Artificial Sequence: Primer

40 <400> 61  
 agatctgcca ccatgccact ctgggtgttc ttctttgtg 39

45 <210> 62  
 <211> 36  
 <212> DNA  
 <213> Artificial Sequence

50 <220>  
 <223> Description of Artificial Sequence: Primer

55 <400> 62  
 ggatccaagc cgcacccttg ctcttgctc ttgggt 36

# EP 1 205 551 A1

5 <210> 63  
 <211> 492  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> Description of Artificial Sequence: Primer

15 <400> 63  
 gggtttttgt ggatccaagg ccgagacgta cctgcgggtc atgaagtgtc gccgcttcgt 60  
 ggaaagcagc tgtgcottca cctacaaaga gtttgagcgg gcgtacatcc ccgagggaca 120  
 gaggtactcc atccagaacg cgcaggccgc cttctgcttc tcggagacca tcccggcccc 180  
 cacgggcaag gacgaggccc agcagcgatc cgacgtggag ctgctccgct tctccctgct 240  
 gctcatccag tctggtctcg ggcccgtgca gtttctcagc aggttcttca ccaacagcct 300  
 gglgttcggc acctcagacc gagtctacga gaagctcaag gacctggagg aaggcatcca 360  
 20 agccctgalg cgggagctgg aagatggcag tccccgggcc gggcagatcc tgaagcagac 420  
 ctacgacaag ttgacacga acctgcgcag tgacgatgcg ctgcttaaga actacgggct 480  
 gctctcctgc tt 492

25 <210> 64  
 <211> 69  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <223> Description of Artificial Sequence: Primer

35 <400> 64  
 ggatccgaag gcaacagctgc tttccacgaa gggcgacac ttcattgaccc gcaggtacgt 60  
 ctcggcctt 69

40 <210> 65  
 <211> 102  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <223> Description of Artificial Sequence: Primer

50 <400> 65  
 agatcttcaa agccgcaccc ttgctccttg ctcttggttt ctctctccct gctgcctgct 60  
 catgatgtcc tggagcagct tgcgggcgga cagctggccc ag 102

55 <210> 66  
 <211> 21

<212> DNA

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence: Primer

10

<400> 66

ccgcggcatc ctgaggggtca a

21

15

<210> 67

<211> 21

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence: Primer

25

<400> 67

tatgcagatg ccatcttcaa c

21

30

## Claims

35

1. A method for the treating growth hormone related disorders **characterized by** growth hormone deficiencies in an animal, comprising supplying the animal with a polynucleotide sequence that encodes growth hormone releasing hormone or modified growth hormone releasing hormone.

40

2. A method for improving the growth and performance of an animal, comprising supplying the animal with a polynucleotide sequence that encodes growth hormone releasing hormone or modified growth hormone releasing hormone.

3. The method of Claim 1 or 2 wherein a polynucleotide sequence encoding growth hormone releasing hormone or modified growth hormone releasing hormone is contained in pharmaceutically acceptable carrier and is administered to an animal.

45

4. The method of Claim 3 in which the carrier is a DNA vector, a viral vector, a liposome or lipofectin.

5. The method of Claim 4 in which the DNA vector is an expression vector.

50

6. The expression vector of Claim 5 containing a polynucleotide sequence of growth hormone releasing hormone or modified growth hormone releasing hormone in operative association with a nucleotide regulatory sequence that controls expression of the polynucleotide.

55

7. The expression vector of Claim 6, wherein said regulatory element is selected from the group consisting of the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, and the swine alpha-skeletal actin promoter.

8. The method of Claim 2 in which the animal is a cat, dog, cow, pig, horse or chicken.

9. A method for the treating growth hormone related disorders **characterized by** growth hormone deficiencies in an animal, comprising supplying the animal with a polynucleotide sequence that encodes growth hormone or modified growth hormone.
- 5 10. A method for improving the growth and performance of an animal, comprising supplying the animal with a polynucleotide sequence that encodes growth hormone or modified growth hormone.
11. The method of Claim 9 or 10 wherein a polynucleotide sequence encoding growth hormone or modified growth hormone is contained in pharmaceutically acceptable carrier and is administered to an animal.
- 10 12. The method of Claim 11 in which the carrier is a DNA vector, a viral vector, a liposome or lipofectin.
13. The method of Claim 12 in which the DNA vector is an expression vector.
- 15 14. The expression vector of Claim 13 containing a polynucleotide sequence of growth hormone or modified growth hormone in operative association with a nucleotide regulatory sequence that controls expression of the polynucleotide.
- 20 15. The expression vector of Claim 14, wherein said regulatory element is selected from the group consisting of the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, and the swine alpha-skeletal actin promoter.
16. The method of Claim 15 in which the animal is a dog, cat, cow, pig, horse or chicken.
- 25 17. A growth hormone releasing hormone (GHRH) variant comprising the addition of one amino acid to the amino terminus of a 29 amino acid amino terminal fragment of GHRH, in a pharmaceutical formulation suitable for delivery to a human or livestock.
18. The growth hormone releasing hormone of Claim 17 wherein the amino acid is a hydrophobic residue or tyrosine.
- 30 19. A growth hormone releasing hormone variant comprising the addition of two or three amino acids to the amino terminus, of a 29 amino acid amino terminal fragment of GHRH wherein the second amino acid is not proline or alanine in a pharmaceutical formulation suitable for delivery to a human or livestock.
- 35 20. A growth hormone releasing hormone variant of Claim 19 comprising the addition of more than three amino acids to the amino terminus of a 29 amino acid amino terminal fragment of GHRH, wherein the addition does not interfere with the functional activity of growth hormone releasing hormone.
- 40 21. The growth hormone releasing hormone variant of Claim 17, 19 or 20, further comprising a substitution of glycine with alanine at residue 15.
22. The growth hormone releasing hormone variant of Claim 17, 19 or 20, further comprising a substitution of leucine with alanine at residue 22.
- 45 23. The growth hormone releasing hormone variant of Claim 17, 19 or 20, further comprising substitutions of glycine with alanine at residue 15 and leucine with alanine at residue 22.
24. The growth hormone releasing hormone variant of Claim 17, 19, or 20, further comprising the addition of glycine and arginine at the carboxy-terminus.
- 50 25. The growth hormone releasing hormone variant of Claim 18, 19 or 20 in which the amino acids are naturally occurring.
26. A polynucleotide sequence encoding the growth hormone releasing hormone variant of Claim 17, 19 or 20.
- 55 27. A nucleotide vector containing the polynucleotide sequence of Claim 26.
28. An expression vector containing the polynucleotide sequence of Claim 26 in operative association with a nucleotide

regulatory sequence that controls expression of the polynucleotide sequence in a host cell.

29. The expression vector of Claim 28, wherein said regulatory element is selected from the group consisting of the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, and the swine alpha-skeletal actin promoter.
30. A genetically engineered host cell that contains the polynucleotide sequence of Claim 26.
31. A genetically engineered host cell that contains the polynucleotide sequence of Claim 26 in operative association with a nucleotide regulatory sequence that controls expression of the polynucleotide sequence in the host cell.
32. A method for the treating growth hormone related disorders **characterized by** growth hormone deficiencies in an animal, comprising supplying the animal with a polynucleotide sequence that encodes the growth hormone releasing hormone variant of Claim 17, 19 or 20.
33. A method for improving the growth and performance of an animal, comprising supplying the animal with a polynucleotide sequence that encodes the growth hormone releasing hormone variant of Claim 17, 19 or 20.
34. A purified polypeptide of the growth hormone releasing hormone variant of Claim 17, 19 or 20.
35. A method for the treating growth hormone related disorders **characterized by** growth hormone deficiencies in an animal, comprising supplying the animal with an effective amount of a polypeptide of Claim 34.
36. A method for improving the growth and performance of an animal, comprising supplying the animal with an effective amount of a polypeptide of Claim 34.
37. A pharmaceutical composition for promoting the expression and elevation of growth hormone in an animal, comprising administering to said animal an effective amount of the growth hormone releasing hormone variant of Claim 17, 19 or 20.
38. A pharmaceutical composition for the treatment of growth hormone related disorders **characterized by** growth hormone deficiencies in an animal, comprising administering to said animal an effective amount of the growth hormone releasing hormone variant of Claim 17, 19 or 20.
39. A pharmaceutical composition for the improvement of growth and performance of an animal, comprising administering to said animal an effective amount of a growth hormone releasing hormone variant of Claim 17, 19 or 20.






FIGURE 1



**FIGURE 2**





**FIGURE 3**




FIGURE 4




FIGURE 5



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 00 30 9965 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 99 05300 A (DRAGHIA AKLI RUXANDRA; SCHWARTZ ROBERT J (US); LI XUYANG (US); EAS) 4 February 1999 (1999-02-04)	1-6,8	C12N15/16 C12N15/62 C12N15/85
Y	* claims 5,45-49 *	17-39	C12N5/10 C07K14/60
X	DRAGHIA-AKLI R ET AL: "ENHANCED GROWTH BY ECTOPIC EXPRESSION OF GROWTH HORMONE RELEASING HORMONE USING AN INJECTABLE MYOGENIC VECTOR" NATURE BIOTECHNOLOGY, US, NATURE PUBLISHING, vol. 15, no. 12, 1 November 1997 (1997-11-01), pages 1285-1289, XP002060954 ISSN: 1087-0156	1-6,8	C07K14/61 A61K38/25 A61K38/27 A61K48/00
Y	* figure 3 *	17-39	
Y	HOFFMAN T ET AL: "Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro oligopeptides ascertained by capillary electrophoresis" JOURNAL OF CHROMATOGRAPHY, vol. 716, 1995, pages 355-362, XP004038599 * table 1 *	17-39	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12N C07K A61K
<p><b>INCOMPLETE SEARCH</b></p> <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claims 1-5, 8, 32, 33, 35 and 36 are directed to methods of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		25 July 2001	Lonnoy, O
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>&amp; : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>			

EPC FORM 1503 03.02 (P04007)



European Patent  
Office

Application Number  
EP 00 30 9965

### CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

### LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

see sheet B



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 00 30 9965

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	US 5 854 216 A (GAUDREAU PIERRETTE) 29 December 1998 (1998-12-29) SeqIdNo.15	17,18, 34-39	
X	EP 0 199 018 A (SERONO CESARE IST RICERCA) 29 October 1986 (1986-10-29) * claim 1 *	17,18,20	
E	EP 1 052 286 A (PFIZER PROD INC) 15 November 2000 (2000-11-15) * the whole document *	1-8, 17-39	
A	WO 92 10576 A (UPJOHN CO) 25 June 1992 (1992-06-25) * claim 12; examples 20-23 *	19,20	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	FELIX A M ET AL: "PEGYLATED PEPTIDES IV ENHANCED BIOLOGICAL ACTIVITY OF SITE-DIRECTED PEGYLATED GRF ANALOGS" INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH,DK,MUNKSGAARD, COPENHAGEN, vol. 46, no. 3/04, 1 September 1995 (1995-09-01), pages 253-264, XP000526320 ISSN: 0367-8377 * table 1 *		
A	REECY J ET AL: "Structure and regulation of the porcine skeletal alpha-actin-encoding gene" GENE, vol. 180, no. 1-2, 1996, pages 23-28, XP004071892		
	---		
	-/--		



European Patent  
Office

**LACK OF UNITY OF INVENTION  
SHEET B**

Application Number

EP 00 30 9965

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

**1. Claims: 1-8 and 17-39 (all totally)**

A pharmaceutical composition comprising a polynucleotide sequence that encodes GHRH or a modified GHRH

**2. Claims: 9-16 (all totally)**

A pharmaceutical composition comprising a polynucleotide sequence that encodes GH or a modified GH



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 00 30 9965

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	<p>KUBIAK T ET AL: "Position 2 and position 2/Ala15-substituted analogs of bovine growth hormone-releasing factor (bGRF) with enhanced metabolic stability and improved in vivo bioactivity"</p> <p>J MED. CHEM., vol. 36, no. 7, 2 April 1993 (1993-04-02), pages 888-897, XP002158524</p> <p>---</p>		
A	<p>WO 96 37514 A (THERATECHNOLOGIES INC) 28 November 1996 (1996-11-28)</p> <p>---</p>		
A	<p>BREDDAM K ET AL: "Amydation of growth hormone releasing factor 1-29 by serine carboxypeptidase catalysed transpeptidation"</p> <p>INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 37, no. 2, 1991, pages 153-160, XP002158525</p> <p>-----</p>		<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p>



**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 9965

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

25-07-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9905300 A	04-02-1999	AU 8589998 A	16-02-1999
		EP 0988388 A	29-03-2000
		JP 2001511353 T	14-08-2001
US 5854216 A	29-12-1998	CA 2158782 A	24-03-1996
EP 0199018 A	29-10-1986	IT 1234977 B	09-06-1992
		AT 84548 T	15-01-1993
		AU 600891 B	30-08-1990
		AU 5484386 A	25-09-1986
		DE 3687470 D	25-02-1993
		DE 3687470 T	19-05-1993
		DK 122486 A	23-09-1986
		ES 553274 D	01-12-1987
		ES 8800722 A	01-02-1988
		FI 861217 A,B,	23-09-1986
		IL 78044 A	18-07-1991
		JP 7010900 A	13-01-1995
		JP 8016120 B	21-02-1996
		JP 2043335 C	09-04-1996
		JP 7079701 B	30-08-1995
		JP 61274686 A	04-12-1986
		JP 2537029 B	25-09-1996
		JP 7316197 A	05-12-1995
		NO 175318 B	20-06-1994
		ZA 8601644 A	29-10-1986
EP 1052286 A	15-11-2000	BR 0001606 A	24-04-2001
		JP 2000350590 A	19-12-2000
WO 9210576 A	25-06-1992	AU 662508 B	07-09-1995
		AU 9116591 A	08-07-1992
		CA 2094512 A	14-06-1992
		CZ 9301093 A	19-01-1994
		EP 0561971 A	29-09-1993
		FI 932680 A	11-06-1993
		HU 69963 A	28-09-1995
		IE 914347 A	17-06-1992
		JP 6503473 T	21-04-1994
		NO 932148 A	09-08-1993
		RU 2114119 C	27-06-1998
		SK 60893 A	06-10-1993
WO 9637514 A	28-11-1996	AT 204881 T	15-09-2001
		AU 697119 B	24-09-1998
		AU 5683396 A	11-12-1996

EPC FORM P0453

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 9965

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

25-07-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9637514 A		BR 9608799 A	07-12-1999
		CA 2222068 A	28-11-1996
		DE 69614849 D	04-10-2001
		EP 0828758 A	18-03-1998
		JP 11505807 T	25-05-1999
		US 6020311 A	01-02-2000
		US 5939386 A	17-08-1999
		US 5861379 A	19-01-1999
-----			

EPO FORM P0458

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82